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Executive summary 
 
Chapter 1: Systematic review 
Background 
 Clinical trials support the use of virtual reality (VR) in the treatment of 
mental disorders, including but not limited to anxiety disorders, post-traumatic stress 
disorder, depression, psychosis, eating disorders and substance misuse. It was first 
developed in the 1960s and has been used to treat specific phobias since the 1980s with 
effect sizes comparable to in vivo exposure. Immersive virtual reality consists of 
stereoscopic head mounted displays with advanced tracking systems. These allow 
movements of the user to mirror a computer-generated avatar within the virtual 
environment. VR technology has advanced in the last three years and consumer 
equipment is now available and easy to use. This has increased interest in using virtual 
reality as a treatment platform and has created real opportunities to disseminate VR 
technology into clinical settings.  
 Specific phobias are characterised by a marked fear of objects or situations that 
persist for several months. Phobias are relatively common within the general population 
with many people experiencing one or more in their lifetime. Subtypes of phobias 
include animal (e.g. spiders), natural environment (e.g. heights), situational (e.g. flying), 
blood injury (e.g. needles), and other (e.g. balloons). Exposure is the primary treatment 
for specific phobias and has a strong evidence base. However, current research suggests 
re-considering approaches that have been used for many years, namely the emotional 
processing model of exposure (Foa and Kozak, 1986) as within session fear reduction 
does not predict outcomes as theorized. Furthermore, habituation to feared stimuli was 
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previously considered the primary mechanism of change but evidence now indicates 
that it only has a partial effect. The inhibitory learning model of exposure consolidates 
cognitive behavioural models and experimental research on fear renewal to create a 
series of recommendations to maximise exposure.  
 Despite evidence to support virtual reality in the treatment of specific phobias in 
comparison to face to face therapies, the therapeutic content of these treatments has yet 
to be systematically reviewed. 
 Aims 
The aim of the systematic review is to evaluate the content of virtual reality 
treatments for specific phobias in the last ten years. As VR systems are disseminated for 
clinical use, it is important to review current applications and to understand the 
treatment mechanisms specific to virtual reality. It is hoped that this will inform the 
design and use of future scenarios.  
Method 
Randomised controlled trials of virtual reality treatments of specific phobias in 
the last ten years were evaluated. Only studies with one (or more) arms of virtual reality 
treatment were included in the review. Studies with participants <18 years old or that 
treated disorders starting in childhood (e.g. neurodevelopmental disorders) and/or 
physical health conditions were excluded. Case reports, dissertations and conference 
papers were also excluded from the review. Embase, Medline, PsychINFO and Pubmed 
were searched to identify studies for the review. The search was closed on 7
th
 February 
2019. 445 studies were screened, and 16 trials were identified as meeting the inclusion 
criteria. 
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Results  
    The main phobias treated in the studies reviewed were fear of heights, fear of 
flying and small animal phobia, including fear of spiders. The samples sizes ranged 
from 15 to 100 and the methodological quality of studies was mixed. Most of the 
studies compared virtual reality to a non-virtual control such as, in vivo or waitlist. 
Medium to large effect sizes were found in on pre and post treatment scores following 
the virtual reality intervention in all studies. Most of the studies collected follow up data 
but this ranged from 1 week to 1-year post intervention and the measures were largely 
self-report. Behavioural avoidance tests were used in nine of the studies but there was 
variability in measurement and some researchers used the same virtual reality scenario 
that had been used in the treatment component.  
Detailed reporting of treatment content was poor, yet most authors provided 
comprehensive descriptions of the virtual environments. The majority of studies used a 
hierarchical model of exposure except for one that used behavioural experiments. Seven 
of the studies used cognitive behavioural techniques but not all reported these in 
sufficient detail to evaluate or replicate the intervention. Most of the studies used 
psychoeducation either at the start or within the virtual scenario and four studies used 
therapeutic components that were external to virtual reality. The number of sessions of 
each intervention ranged from 1 to 16 and the overall time spent in VR from 30 minutes 
to 9.5 hours. 
Few studies compared virtual reality treatments and only one tested individual 
treatment components that investigated stimulus and environmental context as a 
mechanism of change. One study was completely automated and involved a virtual 
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‘therapist’ or ‘coach’ created from a digital avatar within the system. Treatment 
mediators and moderators were not tested in any of the studies. 
Discussion 
It was not surprising that detailed reporting of treatment content was poor, as 
many of the studies reviewed were small and used virtual reality to replicate in vivo 
exposure rather than as a stand-alone treatment. It seemed that researchers were more 
concerned with the believability and immersion of the scenario than the therapeutic 
content. This can be partially explained by the strong emphasis on hierarchical exposure 
and reliance on habituation as a mechanism of change. This approach is now considered 
outdated as the primary method of exposure as fear often returns. However, post 
treatment effect sizes are medium to large, so it is likely that researchers have limited 
motivation to change exposure techniques. The exception was the automated treatment 
that used behavioural experiments to initiate cognitive change. This treatment also used 
many of the recommendations outlined in newer models of exposure and may provide 
insight into the content of future VR treatments.  
Notably, only one study investigated treatment mechanisms by directly 
comparing virtual reality for the same phobia and manipulating a component of the 
scenario. This suggests that virtual reality is largely considered a tool to mirror the real 
world and the full potential of this technology is yet to be explored. One of the main 
advantages of using this virtual reality is to create scenarios that are unachievable or 
impractical to achieve in reality. Therefore, researchers should now focus on treatment 
mediators and moderators by directly comparing scenarios. This will provide a better 
understanding of treatment mechanisms that can be used to inform future developments 
and improve efficacy.  
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Chapter 2: Empirical project 
 Background 
 Fear of heights was one of the first phobias to be treated using virtual 
reality and has since developed a substantial evidence base. Post treatment effect sizes 
have consistently been medium to large and it is as effective as in vivo exposure. Virtual 
reality treatments are being disseminated into clinics, but many continue to use 
hierarchical exposure models that rely on habituation as the primary mechanism of 
change. Exposure does not work for everyone and fear renewal is common. The 
inhibitory learning model consolidates the research on fear extinction and makes a 
series of recommendations to maximise exposure. These include deepening extinction 
(combining phobic cues), violating expectancy (predicted verses actual outcomes), 
removal of safety signals (dropping safety behaviours), variability (varying exposure 
intensity) and using multiple contexts for exposure. Virtual reality provides a unique 
platform to investigate individual components of exposure treatments as scenarios are 
easily adapted and experimental conditions can be maintained. There is limited evidence 
examining treatment mediators and moderators of virtual reality exposure and few 
studies have compared treatments to investigate augmentations. 
 Physiological arousal is associated with fear responses to phobic stimuli. 
However, there is often discordance between subjective and objective measures of 
anxiety in both virtual reality and in the real world. Some people with a fear of heights 
misinterpret anxious arousal as threatening and believe it will increase the likelihood of 
falling. A number of studies have measured physiological responses, but few have 
manipulated arousal.  
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 The evidence for predictors of treatment outcome in specific phobias is 
inconclusive. There is some support for an association between state and trait anxiety in 
spider phobics. Likewise, negative cognitive style and low mood has been found to lead 
to poorer outcomes. Safety seeking behaviours are key maintenance factors in anxiety 
disorders and are central to exposure therapies for phobias. Aversion to risk has not 
been investigated in this population but avoidance is a primary safety behaviour that 
minimises the potential for harm. Therefore, it is possible that this contributes to 
treatment outcome. As new treatments are developed and automated, it is important to 
understand predictors of outcome to ensure therapeutic content is appropriately 
designed.     
     Aims 
The aim of the empirical study is to investigate whether deepening extinction by 
increasing physiological arousal in an automated virtual reality treatment for fear of 
heights enhances cognitive change.  
The primary hypothesis was that deepening extinction by increasing 
physiological arousal in virtual reality would significantly reduce belief conviction in 
comparison to virtual reality alone. The secondary hypothesis was that self-efficacy and 
subjective units of distress would mediate the effect of increased physiological arousal 
on belief conviction. The final hypothesis was that tendency to use safety behaviours, 
risk aversion, mood, trait anxiety, sensitivity to internal phobic cues and self-reported 
fear of heights are predictors of overall belief reduction in virtual reality exposure 
therapy. 
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Design 
A between-participants randomised mixed experimental design was used. 
Participants were randomly assigned to either an exercise condition (increasing 
physiological arousal) or a control condition. The primary outcome was conviction in 
beliefs about heights. This was measured at pre and post-test. Predictor measures were 
taken at baseline, self-efficacy and subjective units of distress were measured at 
multiple timepoints throughout the intervention and heart rate was measured 
continuously from baseline to post-test.  
Method    
60 participants with a fear of heights were recruited from the general public. 
Screening was completed via an online questionnaire (Qualtrics) and eligible 
participants were invited to take part. Participation took approximately 1.5-2hrs in a 
single visit to the VR lab. All participants completed a 30-minute session of an 
automated virtual reality treatment for fear of heights (for original trial see Freeman et 
al., 2018) Participants in the exercise condition cycled to 80% of their maximal heart 
rate prior to entering virtual reality. The control group maintained their resting heart 
rate.  
Analysis and results 
Linear mixed effects models were used to check the manipulation and to test the 
primary hypothesis. The manipulation was effective at increasing physiological arousal 
(p<0.0001) and had a large effect size of (d=2.9). All participants significantly 
improved following the virtual reality intervention (p<0.0001), (d=1.0) but increasing 
physiological arousal did not provide any additional benefit as there was no significant 
difference between the groups (p=0.56), (d=0.1). Self-efficacy improved in both groups 
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(p<0.0001), (d=0.8) but self-reported distress did not significantly change (p=0.98).  
Individual linear regressions were used to test the individual effect of predictor variables 
on the post-test conviction for the whole sample (groups were combined). When 
accounting for baseline conviction, none of the predictor measures were associated with 
post-test belief conviction, including the fear of heights measures.  
Discussion 
The main finding that physiological arousal was not associated with conviction 
change indicates that deepening extinction does not provided added benefit to exposure 
treatments and that arousal is not required to achieve cognitive change in virtual reality. 
One explanation for these findings is that only participants with certain fears about 
heights such as, losing balance or being out of control, appraised physiological arousal 
as threatening. It is also possible that deepening exposure was more robust to fear 
renewal, which this study was not designed to detect as there were no follow up 
measures.  
The improvement in self-efficacy across all participants suggests further 
research is warranted to investigate feelings self-efficacy as a mechanism of change in 
virtual reality treatments. It is also recommended that researchers consider alternative 
methods of increasing arousal such as, mental imagery. Research examining the 
differences between subgroups of height phobics based on threat beliefs is also 
indicated.  
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Chapter 3: Integration, impact and dissemination 
The objective of both the systematic review and the empirical paper was to 
evaluate and extend the literature on the therapeutic content of virtual reality treatments 
for specific phobias. The review identified directions for future research that were 
explored in the empirical paper. Main reflections on the process were the timing of the 
review in relation to the initial study design and ambitious recruitment targets.  
The systematic review will be submitted for publication in ‘Cyberpsychology, 
Behavior and Social Networking’ and the empirical paper will be submitted to 
‘Behaviour Research and Therapy’. It is hoped that both papers will inform the 
development of future virtual reality treatments, including how they are designed, 
disseminated and tested.  
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Chapter 1: Systematic review 
 
Virtual reality for specific phobias: a systematic review  
of treatment content 
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Abstract 
Background 
Clinical trials support the use of virtual reality (VR) in therapy as a viable 
treatment for specific phobias, with effect sizes comparable to in vivo exposure. The use 
of VR for mental health conditions was previously confined to specialist labs. However, 
over the past three years the hardware has become accessible as consumer equipment. 
This has seen a renewed interest in developing VR treatments to be used in clinics.  
Objectives 
The aim of this review is to evaluate the contemporary applications and 
therapeutic content of virtual reality in the treatment of specific phobias to inform the 
development of the next generation of VR treatments.  
Methods 
A systematic search was conducted of randomized controlled trials published in 
the last ten years with one (or more) arms using virtual reality as a treatment for specific 
phobias.  
Results 
445 papers were screened and sixteen trials meeting the inclusion criteria were 
identified. The precise content of the VR treatments was often poorly detailed but most 
used hierarchical exposure models except for one study that used behavioural 
experiments. Most studies used virtual reality to replicate in vivo exposure and none 
tested mediators or moderators of treatment. All studies found medium to large effect 
sizes on the primary outcomes from pre to post treatment.  
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Conclusion 
The basic model of hierarchical exposure to feared stimuli in VR produces good 
clinical effects. However, variability in treatment effects indicates that research is 
needed to establish the most effective way of using VR. A research programme that 
includes study of moderators, mediators, and the effects of single techniques would be 
valuable. Future research should also focus on using the full potential of VR technology 
to deliver novel treatments that enhance cognitive change and reduce fear renewal.   
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Introduction 
Evidence for the use of virtual reality (VR) to treat mental health problems is 
growing but it has mostly been applied to the treatment of specific phobias. This review 
will consider, in depth, how VR has been applied to specific phobias in order to learn 
precisely how the technology has been utilised and to identify potential improvements 
that could deliver greater treatment benefits as VR becomes increasingly used in clinics. 
Specific phobias 
Symptoms of specific phobias are marked by an intense fear and avoidance of 
specific objects or situations with symptoms persisting for several months (DSM-5, 
Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric 
Association, 2013; ICD-11, International Classification of Diseases, 11
th
 revision; 
World Health Organization, 2018). Phobia subtypes according to the DSM-5 are as 
follows: animal (spider, snake, rats, dogs), natural environment (heights, storms, water), 
situational (enclosed spaces, flying, lifts), blood injury (medical procedures, blood, 
needles) and other (choking, vomiting, loud noises, balloons). Animal phobias are the 
most prevalent phobia in the general population and are more common in women, 
usually developing in early childhood. This is closely followed by fear of heights, but 
most people will have more than one phobia (Curtis, 1998). Social phobia and 
agoraphobia are not included in the subtypes of specific phobia and are considered 
separate disorders (Craske & Stein, 2016; LeBeau et al., 2010). 
Specific phobia is a common mental health problem with a lifetime prevalence 
of 18.4% and a 12-month prevalence of 12.1% (Kessler et al., 2004). Phobias often start 
in childhood and have an average age of onset of 8 years old with more women 
experiencing symptoms than men (Wardenaar et al., 2017).  
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Treatment of specific phobias 
Treatments for specific phobias are predominantly exposure-based, such as in 
vivo exposure, virtual reality techniques, imaginal exposure, systematic de-sensitization, 
and Eye Movement Desensitization and Reprocessing (EMDR). Alternative approaches 
used either on their own or in combination with exposure include applied muscle 
tension, applied relaxation, progressive muscle relaxation, and cognitive therapy 
(Wolitzsky-Taylor, Horowitz, Powers & Telch, 2008; Grös & Antony, 2006). Exposure 
treatments involve facing the feared stimulus either in vivo (having direct contact), 
through imaginal techniques or within computer-generated environments. There is 
substantial evidence to support the use of in vivo exposure to treat several phobias 
including, but not limited to, blood injection (see review Ayala, Meuret & Ritz, 2009), 
dental (see review Appukuttan, 2016), spider (Öst, 1996), flying (see review Clark & 
Rock, 2016), heights (Baker, Cohen & Saunders, 1973), choking (see review Sahoo, 
Hazari & Padhy, 2016), vomiting (Veale, 2009) and water (Menzies & Clark, 1993). 
Exposure-based treatments are more efficacious than non-exposure controls, but the 
latter do have some benefit (Choy, Fyer & Lipsitz, 2007), notably cognitive therapy in 
the treatment of claustrophobia (Booth & Rachman, 1992). In vivo is often considered 
the most effective of the exposure treatments, however, comparable effect sizes are 
found in virtual reality for the treatment of phobias (Carl et al., 2019).  
In vivo exposure-based therapies predominantly use habituation models. These 
originate in emotional processing theories of exposure (Foa & Kozak, 1986; Foa & 
McNally, 1996), despite the limitations in evidence to support these models (Craske, 
Kircanski, Zelikowsky, Mystkowski, Chowdhury & Baker, 2008). Habituation is 
achieved by remaining in a feared scenario until anxiety reduces but fear renewal is 
19 
 
common, it doesn’t work for everyone, and within session fear reduction does not 
predict outcomes (Baker, Mystkowski, Culver, Mortazavi & Craske, 2010). This 
suggests habituation is not the only mechanism involved in new learning. The inhibitory 
learning model of exposure provides an alternative understanding that addresses these 
limitations. It originates in the literature on fear extinction and outlines the presence of 
both a primary phobic association between a feared stimulus (e.g. heights) and 
conditioned response (e.g. fear), and a secondary non-fearful association learned during 
exposure. This differs from previous models as exposure does not erase the primary 
association that links the stimulus with a phobic response; it is inhibited by the 
secondary association. Therefore, fear renewal and symptom reduction are dependent on 
the quality and strength of new learning achieved during exposure.  
 Craske and colleagues (2015) collate the literature on inhibitory learning and 
suggest additional mechanisms to maximise exposure by strengthening this secondary 
association. (Craske, 2015). Craske, Treanor, Conway, Zbozinek & Vervliet (2014) 
propose a series of therapeutic techniques that maximise outcomes based on this model 
of exposure. Recommendations include violating expectancy (creating a mismatch 
between what is expected and the outcome), varying exposure intensity (facing stages 
on a fear hierarchy at random), using multiple contexts (more than one setting for 
exposure), deepening extinction (combining phobic cues), and dropping safety seeking 
behaviours. The aim of this approach is to create new learning about the feared stimulus 
(cognitive change).  
Virtual reality  
Virtual reality is an immersive computer-generated environment that allows the 
user to explore and interact with a virtual world. It was first developed in the 1960s, 
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requiring large laboratories with specialist computers (Freeman et al, 2017). These have 
since advanced to portable head mounted displays (HMDs), CAVE automatic virtual 
environments created by multiple projectors within a cube shaped room (CAVE, Cruz-
Neira, Sandin & DeFanti, 1993), and augmented reality headsets (Bhorkar, 2017; Zhu, 
Hadadgar, Masiello & Zary, 2014). Between 2013-2014, Oculus Rift released their 
‘Development Kit 1’ to the public market and by 2016, HTC, HP, Acer, Dell, and Sony 
had all developed similar systems (Jerden, Grindle, Woerden & Boulos, 2018). These 
newer headsets, relatively low in price and easy to set up and support, have now made it 
possible to integrate virtual reality into clinical services, which could prove an 
important part of future mental health care. Furthermore, new developments in 
hardware are expected on the market soon, including VR headsets with advanced, self-
contained tracking capabilities. 
Virtual reality has been used for the treatment of phobias since the mid-1990s, 
with the first applications being used for fear of heights (Rothbaum, et al., 1995a; 
Rothbaum et al., 1995b). These environments involved a series of footbridges and 
balconies at different heights, and a glass elevator that scaled the side of a building. 
Exposure sessions lasted for 35-45 minutes and were delivered weekly for seven weeks. 
Since these early trials, virtual reality has been used for many different mental health 
problems including psychosis, substance misuse, post-traumatic stress disorder (PTSD) 
and eating disorders (for review, see Freeman et al., 2017). The design of these 
environments predominantly targets real world stimuli that can be replicated and 
controlled in virtual reality. In the treatment of PTSD this is trauma related stimuli 
whereas preliminary studies in eating disorders have experimented with changes to the 
body-mass index of the user’s avatar (Keizer, Elburg, Helms & Dijkerman, 2016). 
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Likewise, Freeman and colleagues have pioneered virtual reality to assess (Freeman et 
al., 2003) and treat paranoia (Freeman et al., 2016). Importantly, large effect sizes in 
comparison to controls have been consistently reported for the use of virtual reality for 
specific phobias, notably, animal phobias, fear of flying and fear of heights (for a 
review, see Carl et al., 2019; Maples-Keller, Yasinski, Manjin & Rothbaum, 2017; 
Opriş, Pintea, García-Palacios, Botella, Szamosközi & David, 2012).  
Existing literature and reviews 
 There have been several reviews and meta-analyses of the outcomes for virtual 
reality treatments for anxiety disorders (Benbow & Anderson, 2019; Carl et al., 2019; 
Fodor, Coteț, Cuijpers, Szamoskozi, David & Cristea, 2018; Lindner et al., 2017; 
McCann et al., 2014; Opriş et al., 2012; Meyerbröker & Emmelkamp, 2010; Powers & 
Emmelkamp, 2008; Gorini et al., 2008; Krijn, Emmelkamp, Olafsson & Biemond, 
2004). These included some information about specific phobias but only Parsons and 
Rizzo (2008) evaluated the efficacy and effectiveness of virtual reality treatments in a 
meta-analysis of VR used for anxiety and specific phobias. More recently, Maples-
Keller et al. (2017) discussed the same topic in a narrative review. There were similar 
findings in both reviews, despite being a decade apart; virtual reality exposure was 
found to reduce anxiety and phobias symptoms, but studies were often of poor quality 
with small sample sizes. Recommendations for further research included identifying 
moderators, extending follow up data, and treating other types of phobias. Most of the 
reviews evaluated efficacy but Garcia-Palacios, Botella, Hoffman & Fareget (2007) 
looked at the acceptability of virtual reality treatments for specific phobias. Lower 
refusal rates were found in virtual reality treatments compared to in vivo. Participants 
also preferred virtual reality due to anticipatory anxiety about facing feared stimuli in 
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the real world. Lindner et al. (2017) reviewed virtual reality technology in relation to 
specific phobias and highlighted some of the components that are relevant to modern 
systems such as tracking, gaze, user input and platform choice. This was an informative 
overview of the different components of virtual reality that were overlooked in previous 
reviews. However, the authors are the creators of VIMSE, a new gamified virtual reality 
treatment for spider phobia (Miloff, Lindner, Hamilton, Reuterskiöld, Andersson & 
Carlbring, 2016), and the review focused on this application to illustrate the components 
discussed. The content of current treatments using virtual reality for specific phobias 
has yet to be systematically reviewed.  
Current systematic review 
The current review focuses on a different aspect from the existing literature on 
virtual reality treatments for specific phobias. These previous reviews have 
predominately evaluated the efficacy of virtual reality treatments. Up to date reviews on 
outcomes are important in a field that relies on emerging technology as there is large 
potential for change (e.g. in the capabilities of the hardware and software). The purpose 
of this review is to evaluate and critically appraise the content of virtual reality 
treatments for specific phobias over the last ten years. Virtual reality is simply the 
immersive technology and the content of the treatment could vary widely and hence 
produce different outcome effects. Therefore, the treatment principles and VR content 
are scrutinised in this review. This could identify the most helpful components but also 
treatment ideas that could enhance efficacy. Components of the virtual reality 
treatments in the included studies were extracted and both the clinical implications and 
future directions discussed.  
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Method 
Inclusion criteria 
The inclusion criteria for studies in this review were: studies published in peer-
reviewed journals; adult participant samples (18+) with a specific phobia; randomized 
controlled trials with at least one arm using virtual reality as a treatment modality for 
specific phobias; studies using immersive virtual reality (Head Mounted Display, 
Augmented Reality, or CAVE systems); studies published within the last 10 years of the 
search; and in the English language. Only randomised controlled trials (RCTs) were 
included as they are considered the gold standard of research to evaluate healthcare 
interventions (Schulz, Altman & Moher, 2010). RCTs of psychological interventions 
aim to test these against treatment as usual, wait lists, or alternative interventions (active 
controls). Virtual reality treatments tested in RCTs will be more developed than those 
used in case reports and, similarly, the evidence for effect sizes will be stronger.  
Exclusion criteria 
Dissertations, conference posters and abstracts, theory and assessment studies 
were excluded from the review. Participants <18 years old and child onset disorders 
were excluded due to potentially different treatment needs in these populations. Studies 
within health psychology or that used virtual reality for physical rehabilitation (e.g. fear 
of falling), were also excluded. Where multiple papers were published from the same 
trial, the study with the main outcome data on the virtual reality intervention was 
reviewed. 
Search strategy 
Four electronic social science databases were searched to identify studies 
relevant to this review. Ovid search engine was used for Embase, Medline and 
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PsycINFO. An additional search was carried out on Pubmed. The search was closed on 
7
th
 February 2019. The general search terms used for each concept were as follows: 
“virtual reality” AND treatment OR therapy OR intervention OR exposure AND 
*phobia OR *phobic OR phobia* OR “fear of”. 
An additional restriction of papers published in English (language) was applied. 
The search was limited to Titles and Abstracts in all four databases. ‘Anxiety’ was not 
used as a search term to identify studies looking at specific phobias despite falling under 
anxiety disorders, as the content of these results was too broad. Search results were 
exported to Mendeley reference management software. Duplicates were removed and 
the title and abstract of 445 studies were screened for eligibility. This initial screening 
excluded 396 studies and identified 49 that potentially met the inclusion criteria. Full 
text versions of these studies were all accessed online and screened for eligibility.  A 
total of 16 studies met the inclusion criteria and were included in this review. Figure 1 
shows the PRISMA flow diagram for the process of identifying, screening and selecting 
papers for the review.  
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Figure 1. PRISMA flow diagram of systematic literature review 
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Screening co-rating 
Two independent researchers (Research Clinical Psychologists) discussed and 
confirmed inclusion and exclusion criteria for the review. 
Quality assessment 
The quality of studies included in this review were assessed using an appraisal 
tool adapted by the researcher to evaluate the risk of bias in selection, allocation, 
detection, attrition and reporting (see Table 1). The tool was informed by the Critical 
Appraisal Skills Programme (CASP, 2014), the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins & Green, 2011), and the Jadad scale (Jadad et al., 
1996). The Jadad is a three-point scale ranging from 0-5 that is commonly reported to 
assess the quality of RCTs. However, Higgins and Green explicitly discourage the use 
the scored rating scales, including the Jadad, due to a disproportionate emphasis on the 
reporting of trials rather than the conduct. As such, the Jadad score for each study is 
included for reference only and is intended to be used in combination with the other 
factors outlined in the tool. The following websites were checked for trial registration: 
https://clinicaltrials.gov and http://www.isrctn.com. If a trial was registered elsewhere 
but the details were reported by the authors, it was classified as registered. Only trials 
that did not report these details and could not be found on the stated websites were 
described as unregistered. As registration to the ISRCTN requires a fee, 
clinicaltrials.gov was also used as this is a free service.
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Table 1. Quality appraisal 
  
Study Jadad 
Score 
N Allocation 
Concealment 
Primary 
outcome 
stated 
Power 
analysis 
stated 
Recruitment 
methods 
reported 
Sample 
represented the 
clinical 
population 
Trial 
registered 
Minns et al. 
(2019) 
2 77 None reported × ×  ×  
Gujjar et al. 
(2019) 
4 30    ×   
Freeman et al. 
(2018) 
5 100       
Lima et al. 
(2018) 
1 36 × × × × Cannot tell × 
Meyerbröker et 
al. (2018) 
5 56     Cannot tell  
Jaquart et al. 
(2017) 
3 59 ×      
Botella et al. 
(2016) 
5 63       
Triscari et al. 
(2015) 
 
3 65 × × ×    
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Table 1 (continued).                       
Shiban et al. 
(2015) 
3 58 None reported × ×   × 
Moldovan & 
David (2014) 
3 32  × × × Cannot tell × 
Tart et al. (2013) 5 29    × Cannot tell  
Rus-Calafell et 
al. (2013) 
1 15 × × × × Cannot tell × 
Meyerbröker et 
al. (2012) 
3 67   ×    
Tortella-Feliu et 
al. (2011) 
1 60 ×  ×   × 
Quervain et al. 
(2011) 
5 40  × ×  × × 
Michalszyn et al. 
(2010) 
 
0 32 × × ×  × × 
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Results 
Treatment effects 
Treatment effects for each study were reported to evidence the efficacy of the 
virtual reality treatments included in this review. As virtual reality is still relatively new, 
variation between studies is expected so it is important to evidence the efficacy of each 
virtual intervention before evaluating individual treatment components.  
To evaluate treatment effects, Cohen’s d was reported for pre and post-test 
scores on the primary outcome. Effect sizes according to Cohen (1988) are as follows: 
small (d=0.20), medium (d=0.50) and large (d=0.80). In studies that compared virtual 
reality to a non-virtual reality control, between group effect sizes were reported. In the 
studies that compared two or more virtual reality conditions or with active controls (in 
vivo or imaginal exposure), within group effect sizes were reported. In studies that 
compared pharmacological augmentations to virtual reality, the placebo condition was 
used to calculate the within groups effect size. If effect sizes were not reported by the 
authors they were calculated by dividing the difference in means with the shared 
standard deviation. In within group effect sizes, the difference in means was divided by 
the pre-test standard deviation. The exception to this was Shiban et al. (2015) as there 
was no obvious control condition so within group effect sizes for all four conditions 
were reported.   
Eleven studies used self-report measures for their primary outcome (Minns et 
al., 2019; Gujjar et al., 2019; Freeman et al., 2018; Lima at el., 2018; Meyerbröker et 
al., 2018, 2012; Jaquart et al., 2017; Triscari et al., 2015; Shiban et al., 2015; Rus-
Calafell et al., 2013; Tart et al., 2011; Quervain et al., 2011). Three studies used 
30 
 
behavioural avoidance tests (Tart et al., 2013; Botella et al., 2016; Michalszyn et al., 
2010) and one study failed to report their data (Moldovan & David, 2014).  
Of the fifteen studies with primary outcome data, the majority reported large 
effect sizes ranging from d=0.85 to d=2.09. The three studies comparing virtual reality 
to in vivo or imaginal exposure reported small or medium between group effect sizes but 
larger within group effect sizes for their virtual reality conditions. Botella et al. (2016) 
and Michalszyn et al. (2010) found large effect sizes between d=1.0 and d=1.96.  
Rus-Calafell et al. (2013) was the only study to find a medium effect size for the virtual 
condition (d=0.61).  
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Table 2. Treatment effects 
Study Primary outcome Control 
condition 
Pre-post between 
group effect size 
(Cohen’s d) with 
95% confidence 
intervals [CI] 
 
Pre-post within 
group effect size 
(Cohen’s d) with 
95% confidence 
intervals [CI] for 
the virtual reality 
condition 
 
Minns et al. (2019) Fear of spiders questionnaire (FSQ; 
Szymanski & O’Donoghue, 1995) 
 
Participants watched a neutral 
video on a computer monitor 
and received psychoeducation 
only 
 
0.85* 
CI [0.384 to 1.32] 
 
- 
Gujjar et al. (2019) Visual analogue scale in the 
assessment of dental phobis (VAS-
A; Luyk, Beck & Weaver, 1988) 
 
Informational pamphlet 1.52* 
CI
a
 
- 
Freeman et al. (2018) Height interpretations questionnaire 
(HIQ; Steinman & Teachman, 2011) 
 
Usual care 2.0*** 
CI [1.84 to 2.51] 
 
- 
Lima et al. (2018) Storm fear questionnaire (SFQ; 
Nelson, Vorstenbosch & Antony, 
2014) 
Progressive muscle relaxation 
and psychoeducation 
0.72* 
CI
a 
- 
Note: a = statistic not reported and data not available; p<0.05*; p<0.01**; p<0.001*** 
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Table 2 (continued). 
Triscari et al. (2015) Flight anxiety sensitivity questionnaire 
and flight modality questionnaire 
(FAS, FAM; Van Gerwen, Spinhoven, 
Van Dyck & Diekstra, 1999) 
 
 
FAS total 
 
FAM total 
 
Active controls (CBT 
EMDR and CBT systematic 
de-sensitization). Within 
group effect size reported 
for VR only condition. 
 
 
 
 
 
 
 
- 
 
- 
 
 
 
 
 
 
2.0*** 
CI
a 
2.22*** 
CI
a 
 
Shiban et al. (2015) Fear of spiders questionnaire – 
German version (FAS; Rinch, 
Bundschuh, Engler, Muller, Wissmann 
& Ellwort, 2002) 
 
 
No non-VR control. Within 
group effect sizes calculated 
for each arm. 
 
VR (single stimulus/single  
context) 
VR (multiple stimulus/single 
context) 
VR (multiple stimulus/multiple 
context) 
VR (single stimulus/multiple 
context) 
 
 
 
 
- 
 
- 
 
- 
 
- 
 
 
 
 
0.75
a
 
CI
 a
 
1.84
a
 
CI
 a
 
2.36
a
 
CI
a
 
0.85
a 
CI
 a
 
Note: a = statistic not reported and data not available; p<0.05*; p<0.01**; p<0.001*** 
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Table 2 (continued). 
Moldovan & David 
(2014) 
Data not reported  
 
Wait list Data not reported  Data not reported 
 
Tart et al. (2013) 
 
Behavioural avoidance test (BAT) 
 
 
No non-VR 
condition. 
Within group 
effect size 
calculated for 
VR with 
placebo. 
 
 
- 
 
 
1.79** 
CI
a
 
 
Rus-Calafell et al. 
(2013) 
Fear of flying scale (FFS; Haug, Brenne, Johnsen, 
Berntzen, Götestam & Hugdahl, 1987) 
 
Active control 
(imaginal 
exposure). 
Within group 
effect size 
reported for VR 
only condition. 
 
- 0.61* 
CI
a
 
 
Meyerbröker et al. 
(2012) 
Flight anxiety modality questionnaire (FAQ;  
Ven Gerwen et al., 1999) 
 
No non-VR 
condition. 
Within group 
effect size 
calculated for 
VR with 
placebo. 
- 1.55
a 
CI
a
 
 
Note: a = statistic not reported and data not available; p<0.05*; p<0.01**; p<0.001*
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Table 2 (continued). 
Tortella-Feliu et al. 
(2011) 
Fear of flying questionnaire (FFQ; Bornas, 
Tortella-Feliu, Garcia de la Banda, Fullana & 
Ilabrés, 1999) 
 
Active controls 
(computer assisted 
exposure with 
therapist and self-
administered 
computer assisted 
therapy). Within 
group effect size 
reported for VR 
only condition. 
 
- 
 
 
 
 
1.68
a 
CI
a
 
 
 
 
Quervain et al. 
(2011) 
Acrophobia questionnaire (AQ; Cohen, 1977) 
 
No non-VR 
condition. Within 
group effect size 
calculated for VR 
with placebo. 
 
- 0.94
a 
CI
a
 
 
Michalszyn et al. 
(2010) 
Behavioural avoidance test (BAT) Active control.  
Within group effect 
size reported for VR 
only condition. 
- 
 
 
1.96
a 
CI
a
 
 
 
Note: a = statistic not reported and data not available; p<0.05*; p<0.01**; p<0.001*** 
35 
 
Recruitment and sample formation 
Recruitment methods differed across studies which increased the likelihood of 
selection bias. Seven studies recruited from the general population using local radio, 
newspapers adverts, flyers or word of mouth (Freeman et al., 2018; Jaquart et al., 2017; 
Botella, Perez-Ara, Bretón-López, Quero, García-Palacios & Baños, 2016; Shiban, 
Schelhorn, Pauli & Mühlberger  2015; Meyerbröker et al., 2012; Tortella-Feliu et al., 
2011). Three studies recruited from University populations, of which one offered 
undergraduate course credits in return for participation (Minns et al., 2019) and the 
other two studies recruited using flyers and adverts (Quervain et al., 2011; Michalszyn 
et al., 2010). Two studies recruited from outpatient clinics (Gujjar, van Wijk, Kumar & 
de Jongh, 2019; Triscari, Faraci, Catalisano, D’Angelo & Urso, 2015), one used 
participants on waiting lists for previous research trials (Meyerbröker, Morina & 
Emmelkamp 2018) and three did not report their recruitment methodology (Lima, 
McCabe-Bennett & Antony, 2018; Moldovan & David, 2014; Tart et al., 2013).  
Only six of the studies justified their sample sizes and reported power calculations 
(Gujjar et al., 2019; Freeman et al., 2018; Meyerbröker et al., 2018; Jaquart et al., 2017; 
Botella et al., 2016; Tart et al., 2015). Studies with small sample sizes may be 
underpowered to detect both statistical and clinical change. Without power calculations 
the results are difficult to interpret. Exceptions to this standard are pilot studies which 
are usually underpowered. The recommendation for these trials is to report confidence 
intervals (Lee, Whitehead, Jacques & Julious, 2014).  
Participant characteristics 
Eight hundred and nineteen participants from sixteen studies were included in 
this review. The sample size ranged from 15 (Rus-Calafell, Gutiérrez-Maldonado, 
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Botella & Baños 2013) to 100 (Freeman et al., 2018) with a mean of 51 participants 
across all studies. There were proportionately more female participants (63.7%) than 
male (36.3%) but four studies did not report these data, excluding 182 participants from 
this calculation (Meyerbröker et al., 2018; Tart et al., 2013; Meyerbröker et al., 2012; 
Michaliszyn et al., 2010). All studies used adult samples (18+ years) and the mean age 
of participants was 32.3 years old, ranging from 19.3 to 45.5 years old. Two studies did 
not report the mean age of their participants and referred only to the inclusion criteria 
(Moldovan & David, 2014; Meyerbröker et al., 2012). Ten studies were conducted in 
European countries, five from North America and one from Asia. Only four studies 
reported data on the ethnicity of their participants (Gujjar et al., 2019; Freeman et al., 
2018; Lima et al., 2018; Jaquart et al., 2017). These studies recruited participants from 
Malaysia, the United Kingdom, Canada and the United States of America and were 
62.6% Caucasian, 24.7% Asian, 5.3% Other/not reported, 3.1% Black Afro-Caribbean, 
2.6% Black American, 1.1% Middle Eastern and 0.5% Hispanic.  
Phobia  
All studies tested virtual reality treatments for specific phobias. Two studies 
included two or more phobias in the trial, using different virtual reality scenarios for 
each phobia (Meyerbröker et al., 2018; Moldovan & David, 2014). This resulted in 
smaller samples for each group and differences in treatment, particularly in Moldovan 
& David’s (2014) study, which included participants with fear of flying, fear of heights 
and social phobia. Four studies included participants with spider or small animal phobia 
(Minns et al., 2019; Botella et al., 2016; Shiban et al., 2015; Michaliszyn et al., 2010). 
Four studies included participants with a fear of flying only (Triscari et al., 2015; Rus-
Calafell et al., 2013; Meyerbröker et al., 2012 & Tortella-Feliu et al., 2011). Four 
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studies included participants with a fear of heights only (Freeman et al., 2018; Jaquart et 
al., 2011; Tart et al., 2013 & Quervain et al., 2011). One study included participants 
with a dental phobia (Gujjar et al., 2019) and one included participants with storm 
phobia (Lima et al., 2018).  
Most of the studies (n=12) used The Diagnostic and Statistical Manual of 
Mental Disorders 4
th
 Edition (DSM-4, American Psychiatric Association, 1994) or 5th 
Edition (DSM-5; American Psychiatric Association, 2013) to assess presence of specific 
phobias and eligibility for participation. Six studies used self-report measures either on 
their own or in combination with the DSM-4/5, and/or a behavioural avoidance test 
(BAT) (Minns et al., 2019; Gujjar et al 2019; Freeman et al., 2018; Lima et al., 2018; 
Meyerbröker et al., 2018; Jaquart et al., 2017; Michalszyn et al., 2010). Only four 
studies included a BAT to assess eligibility, two of these were in vivo tests involving a 
live tarantula that was rated on proximity to the vivarium, subjective units of distress 
ratings (SUDS) and level of interaction with the spider (Minns et al., 2019; Michalszyn 
et al., 2010). The other two studies using BATs used the virtual reality fear of heights 
scenarios used in the treatment phase and the ratings were based on progression through 
the scenarios and SUDS (Jaquart et al., 2017; Tart et al., 2013).  
Conditions 
Nine of the studies compared virtual reality to a non-virtual reality control. 
These included in vivo (Botella et al., 2016 & Michalszyn et al., 2010), waitlist (Minns 
et al., 2019; Freeman et al., 2018; Moldovan & David et al., 2014), muscle relaxation 
(Lima et al., 2018), information pamphlet (Gujjar et al., 2019) and imaginal exposure 
(Rus-Calafell et al., 2013). The other seven were manipulation studies comparing two or 
more virtual reality treatments. Augmentations of components external to virtual reality 
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included drug augmentations (Meyerbröker et al., 2018; 2012; Tart et al., 2013; 
Quervain et al., 2011) and exercise (Jaquart et al., 2017). Manipulations directly to the 
virtual reality treatment included changes to the environment (Shiban et al., 2015) and 
whether it was self-administered (Tortella-Feliu et al., 2015) or automated (Freeman et 
al., 2018).  
Outcome measures 
All sixteen studies used a combination of disorder specific self-report measures 
at pre and post treatment. Fourteen studies collected follow up data that ranged from 2 
weeks to 1-year post treatment. Minns et al, (2019) did not collect follow up data but 
the post treatment timepoint was 1 week after the intervention. Likewise, Meyerbröker 
et al, (2012) also didn’t use follow ups but collected data at each intervention session in 
addition to pre and post.  
 Nine studies used BATs. Five used in vivo tests, involving a live spider or 
cockroach contained within a vivarium (Minns et al., 2019; Botella et al., 2016; Shiban 
et al., 2015; Michalszyn et al., 2010), dental procedures (Gujjar et al., 2018) or a flight 
of stairs in a tall building (Quervain et al., 2011). The in vivo BATs were used at 
screening, pre, post and follow up timepoints. Three studies used BATs in virtual 
reality. These tasks were based on scenarios used during the intervention phase, for 
example, a glass elevator or a storm. Lima et al. (2018) and Tart et al. (2013) used the 
virtual BATs to measure change at pre and post treatment but Jaquart et al. (2017) used 
it only to assess eligibility.  
Treatment content 
The data extracted on the content of treatment are separated into two parts: the 
virtual environment and therapeutic components. 
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Virtual reality environments  
Table 4 summarises the components of the virtual environments, the specific 
technology used in each study, and a brief overview of the scenarios.    
Technology  
Most of the studies used head mounted displays (HMDs) except for Moldovan 
& David (2014) who also used a CAVE automatic virtual environments (CAVE), cubed 
shaped rooms with multiple projectors. HMDs are wired headsets that display an image 
in each eye, providing a stereoscopic scene similar binocular vision. Only one study in 
the review used a monoscopic HMD (Michalszyn et al., 2010). Typically, HMDs use 
tracking to mirror the movements of the user in the virtual environment (i.e. to enable 
interactive experiences). In newer models, such as the Oculus Rift and HTC Vive, the 
tracking is greatly improved, reducing the effect of cybersickness and improving 
presence. Six of the studies described which systems they used (Minns et al., 2019; 
Freeman et al., 2018; Shiban et al., 2015; Rus-Calafell et al., 2013; Meyerbröker et al., 
2012; Tortella-Feliu et al., 2011), four described only the type of technology (Lima et 
al., 2018; Moldovan & David, 2014; Quervain et al., 2011; Michalszyn et al., 2010), 
and four did not report these details (Meyerbröker et al., 2018; Jaquart et al., 2017; 
Triscari et al., 2015; Tart et al., 2013). One study used an augmented reality headset 
overlaying the real world with virtual environments (Botella et al., 2016). 
Sensory feedback  
It was assumed that all sixteen studies used visual displays as this is a 
fundamental aspect of virtual reality systems. Three studies did not report sufficient 
detail on the technology or exposure techniques used to establish whether additional 
sensory information was included (Jaquart et al., 2017; Trsicari et al., 2015; Tart et al., 
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2013). Nine studies used visual and auditory feedback. The ‘virtual coach’ used by 
Freeman et al (2018) provided psychoeducation, explained the concept of safety 
behaviours and asked how safe the participant was feeling. This treatment used voice 
recognition to respond to participant answers, which was not reported in any of the 
other studies. Rus-Calafell et al. (2013) and Tortella-Feliu et al. (2011) both used the 
Virtual Flight® program designed by the Botella and Baños research team (Botella, 
Osma, Garcia-Palacios, Quero & Baños, 2004). This environment simulated sounds that 
are routinely heard at an airport and during take-off. Participants were passive observers 
and did not interact with avatars in the environment, the content of the audio was 
designed to increase anticipatory anxiety.   
In addition to visual and auditory content, five studies used tactile feedback. 
Meyebröker and colleagues used a vibrating airline chair to simulate flying in both their 
2018 and 2012 studies, and Lima et al. (2018) augmented a virtual reality treatment for 
storm phobias by using a wooden platform that vibrated with woofers playing sounds of 
thunder and lightning. Quervain et al. (2011) used a raised wooden platform that didn’t 
provide active feedback but if the participant walked near the edge they would have 
experienced the feeling of a ledge. Similarly, Gujjar et al. (2019) asked participants to 
sit in a dentist’s chair during the virtual reality session to replicate the feeling of being 
in a clinic room. Gujjar and colleagues were also the only research team to include 
olfactory feedback in the form of clove oil on the chair to simulate clinical smells 
associated with being at the dentist.  
The scenarios were reported as either seated or standing with variation as to 
whether participants were passive or could move freely through the virtual environment. 
Eight of the treatments were seated and were designed for small animal phobia 
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(including spiders), fear of flying, dental phobia and storm phobia (Gujjar et al., 2018; 
Meyerbröker et al., 2018 & 2012; Botella et al., 2016; Shiban et al., 2015; Rus-Calafell 
et al., 2013; Tortella-Feliu et al., 2011 & Lima et al., 2018). The seated position 
matched the avatar in the dental phobia treatment as the scenario took place in a 
dentist’s chair. It also matched the final element of the flying treatments that involved 
sitting on an aircraft waiting for take-off. However, it was not clear from the remaining 
studies whether there was discordance between the avatar’s position in the virtual 
environment and the participant’s position in the room. This has the potential of 
negatively affecting presence in the virtual environment and reducing anxious responses 
to feared stimuli.  
Five studies required participants to stand in virtual reality for the treatment of 
fear of heights scenarios (Freeman et al., 2018; Meyerbröker et al., 2018; Jaquart et al., 
2017; Tart et al., 2013; Quervain et al., 2011). In all five of these studies the participants 
were also able to move freely through the virtual environment. Two seated treatments 
for small animal and spider phobia allowed participants to control their movement in the 
virtual scenarios. Shiban et al. (2015) allowed participants to change the perspective of 
their avatar by using a computer joystick whereas Botella and colleagues (2016) used an 
augmented reality system allowing participants to use their own hands to interact with 
virtual cockroaches and spiders. Four studies in this review did not report on the 
position of their participants during the treatment (Minns et al., 2019; Triscari et al., 
2015; Moldovan & David, 2014; Michalszyn et al., 2010).  
Type of exposure  
Thirteen of the studies in this review used hierarchical exposure for the model of 
treatment in virtual reality, which involved exposing participants to scenarios of 
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increasing difficulty. Participants were either asked to stay in the environment until their 
anxiety reduced as measured by subjective units of distress scales (Jaquart et al., 2017; 
Tart et al., 2013; Rus-Calafell et al., 2013; Tortella-Feliu et al., 2011; Quervain et al., 
2011) or for ‘as long as possible’ within a specified time limit (Minns et al., 2019; 
Gujjar et al., 2019; Meyerbröker et al., 2018, 2012; Botella et al., 2016; Shiban et al., 
2015). The only study to report a different exposure model was Freeman et al. (2018) 
who used a series of behavioural experiments and based progression on belief ratings 
and task completion. Two studies did not report the content of the exposure used in 
virtual reality (Triscari et al., 2015; Michalszyn et al., 2010).  
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Table 3. Scenario summaries and components of virtual reality environments  
Study Senses 
 
Standing or sitting  Move freely 
through 
scenario 
VR system  Scenario summary 
Minns et al. (2019) Visual NR × HMD: 
Oculus Rift  
 
A Grammostola rosea spider 
(tarantula) in different scenarios, 
gradually getting closer to the 
participant. 
 
Gujjar et al. (2019) 
 
Visual 
Auditory 
Olfactory 
 
Sitting 
 
× 
 
HMD: 
Oculus 
development kit 2  
 
The dentist’s clinic room with 
scenarios increasing in difficulties 
(teeth examined to the dentist 
holding a drill).  
 
Freeman et al. 
(2018) 
 
Visual  
Auditory 
 
Standing 
 
 
 
HMD: 
HTC Vive, 
headphones, 
microphone 
 
Participant is supported by a 
‘virtual coach’ to complete tasks 
overlooking a large atrium. Tasks 
include throwing balls over the 
edge and rescuing a cat from a 
tree. Oxford VR software. 
 
Lima et al. (2018) Visual 
Auditory 
Tactile 
Seated  HMD: brand not 
reported, speakers 
in chair. Vibrating 
platform. 
Participants started inside a house 
and ventured outside into different 
extremes of weather. Virtually 
Better software. 
Abbreviations: NR, not reported; HMD, head-mounted display; CAVE, cave automatic virtual environment 
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Table 3 (continued). 
Meyerbröker et al. 
(2018) 
Visual 
Auditory 
Tactile  
Sitting (flying) 
Standing (heights) 
  
(heights only) 
Not reported The flying scenario involved 
taking off, in flight turbulence 
and landing. The heights 
scenario was a series of floors 
in a shopping mall that 
participants could walk to by 
stairs or via a lift. They could 
look over the edge and change 
the floor to glass.  
 
Jaquart et al. (2017) NR Standing   
Remote 
control 
Not reported Participants went up a 35-story 
building in a glass elevator. 
They could look over the edge 
of the railings and move around 
the space. Virtually Better 
software.  
 
Botella et al. (2016) Visual Sitting  HMD: 
Augmented reality 
(Vuzix) 
Spiders and cockroaches 
projected near to and onto the 
hands of the participants and 
therapists by augmented reality.  
Abbreviations: NR, not reported; HMD, head-mounted display; CAVE, cave automatic virtual environment 
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Table 3 (continued). 
Triscari et al. 
(2015) 
 
NR NR NR Not reported Treatment detail not reported. 
Shiban et al. (2015) Visual Seated  
(joystick) 
HMD: 
Z800 3D Visor  
Participants were exposed to 
different dark basements 
(contexts) and different spiders 
(stimuli). They were then asked 
to look around the basement, 
housing one of the spiders using 
a joystick to steer gaze.  
 
Moldovan & David 
(2014) 
Visual 
Auditory 
 
NR NR HMD: brand not 
reported. CAVE: 
system using 
multiple projection 
screens. 
 
Treatment detail not reported. 
 
Tart et al. (2013) NR Standing  Not reported Participants went up a hotel glass 
elevator and explored a series of 
balconies and walkways.  
Abbreviations: NR, not reported; HMD, head-mounted display; CAVE, cave automatic virtual environment 
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Table 3 (continued). 
Rus-Calafell et al. 
(2013) 
Visual 
Auditory 
 
Sitting × HMD: 5DT HMD Participants progressed through 
three levels: packing at home, 
arriving at the airport and waiting 
for take-off.  Virtual Flight® 
software. 
 
Meyerbröker et al. 
(2012) 
Visual 
Auditory 
Tactile 
Sitting × Stereoscopic 
glasses: Cybermind 
Visette Pro 
stereoscopic 
glasses. Vibrating 
aircraft seats. 
 
A series of 25-minute flights in 
different weather conditions and 
increasing technical issues with 
the aircraft.  
Tortella-Feliu et al. 
(2011) 
Visual 
Auditory 
 
Sitting × HMD: 5DT HMD 
800 
See Rus-Calafell et al. (2013)  
Virtual Flight® software. 
 
Quervain et al. 
(2011) 
Visual 
Auditory 
Tactile 
Standing  HMD: brand not 
reported 
Participants progressed through 
an environment with a series of 
bridges and elevators, connecting 
platforms of variable height.  
 
Michalszyn et al. 
(2010) 
Visual 
 
NR   
(mouse) 
Monoscopic I-
glasses brand not 
reported 
Participants confronted a large 
black widow spider.  
Abbreviations: NR, not reported; HMD, head-mounted display; CAVE, cave automatic virtual environment 
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Therapeutic components 
Table 4 summaries the therapeutic components of virtual reality treatments in 
each study. 
Length of treatment 
Most interventions were delivered in 20-30 minute sessions. This dictated 
session doses in most of the studies, requiring short breaks to alleviate potential fatigue, 
eyestrain, or nausea. The exception was Botella and colleagues (2016) who used 
augmented reality for 3 hours as users are less likely to experience sickness with these 
headsets. Cybersickness is a motion related issue that may stem from tracking delays 
between the headset and the virtual environment or in scenarios where the virtual 
environment does not match the user’s movements, causing symptoms similar to motion 
sickness (Rebenitsch & Owen, 2016). As augmented reality systems combine real and 
virtual worlds, tracking delays are less problematic.  
Eight studies used virtual reality for a single intensive session ranging from 30 
minutes to 3 hours in duration. The remaining interventions were delivered in multiple 
sessions over a period of days and weeks. The most amount of time participants spent in 
virtual reality were reported by Triscari et al. (2015), Rus-Calafell et al. (2013) and 
Michalszyn et al. (2010) at 6 hours, 6-7.5 hours and 9.5 hours respectively. However, 
large effect sizes were found across studies regardless of time. The number of sessions 
largely reflected the amount of time in virtual reality, except for Triscari and colleagues 
who reported 16 sessions and only 6 hours in virtuo. Their pre and post effect size was 
one of the largest in the review (d=2.0) but most of their intervention involved in vivo 
tasks such as visiting air traffic control, speaking to a pilot, and participating in a 
simulated take off. In addition, the content of the virtual reality component of the 
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intervention was not reported by the authors. There was no trend in the number or 
length of sessions according to the phobia being treated.  
Therapist involvement 
Six studies used therapists during the virtual reality treatment. Rus-Calafell et al. 
(2013), Tortella-Feliu et al. (2011) and Quervain et al. (2011) reported minimal details 
on therapist involvement but described them as ‘guiding’ participants through the 
environment. Quervain and colleagues asked participants to move their heads around 
and to refrain from using cognitive avoidance behaviours. Tart et al. (2013) reported a 
more active role for their therapist who taught participants to approach feared stimuli 
and to challenge dysfunctional beliefs. The most involved therapists during the virtual 
reality scenarios were in Freeman and colleagues’ (2018) automated treatment (in which 
the therapist was a virtual character) and Botella and colleagues’ (2016) augmented 
reality treatment. The automated treatment was the only study to use a virtual therapist 
or ‘coach’ to guide participants through the scenario. Participants were encouraged to 
drop their safety behaviours and challenge beliefs about heights by completing a series 
of behavioural experiments. The virtual therapist interacted with participants and 
responded to their progress, using phrases such as “that’s great, you’re doing really 
well” and “do you feel safer than you did when you first arrived on this floor?”.  
The Botella et al. (2016) study was the only study to use augmented reality and a 
therapist that was visible to participants during virtual reality. This was made possible 
by the type of headset and influenced the capacity of therapist involvement. Therapists 
in this study used a single session exposure using modelling techniques. Botella and 
colleagues used the real therapist to model interaction with the feared stimuli whereas 
Minns et al. (2019) used the pre-recorded video for the same purpose.  
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Additional treatment components  
Most of the studies in the review used virtual reality on its own as a treatment 
with variations in dose, time spent in virtual reality, the scenario design and therapist 
involvement. However, four out of sixteen reported additional components as well as 
psychoeducation. Triscari and colleagues (2015) went far beyond the virtual reality 
treatment, including cognitive behavioural therapy, a visit to air traffic control and a 
demo flight that simulated aircraft departure. These elements were the same across all 
their conditions and were reported in detail in the paper, yet the virtual reality 
component was not specified. Moldovan and David (2013) also provided additional 
cognitive behavioural sessions outside of their virtual reality treatment and failed to 
detail any of their treatment components. Relaxation and diaphragmatic breathing were 
provided by Rus-Calafell et al. (2013) in the form of homework and as a filler to reduce 
anxiety between experimental conditions by Shiban et al. (2015).  
Psychoeducation 
Twelve of the studies used psychoeducation at the start of therapy. This largely 
involved providing the rationale for exposure, the value of approaching feared stimulus, 
and the purpose of using virtual reality as a treatment modality. Psychoeducation was 
mostly delivered by the researchers apart from Freeman and colleague’s (2018) who 
used a ‘virtual coach’ to guide participants through an automated treatment. In this 
study, psychoeducation about fear of heights and cognitive behavioural therapy was 
provided both at the beginning and throughout the intervention. In two studies, 
psychoeducation was delivered without the presence of a researcher. Minn et al. (2019) 
showed participants a brief video on a computer screen and Tortella-Feliu et al. (2011) 
provided participants with an informational leaflet. Triscari and colleagues (2015) were 
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the only researchers to deliver psychoeducation in a group format at the beginning and 
end of therapy. This was the longest intervention in the review and three sessions were 
dedicated to psychoeducation alone.   
Cognitive behavioural techniques 
Seven of the studies used cognitive behavioural techniques during virtual reality. 
Most of these involved challenging beliefs about the feared stimulus but no information 
was provided on how this was achieved (Jaquart et al., 2017; Triscari et al., 2015; 
Moldovan & David et al., 2014; Tart et al., 2013 & Rus-Calafell et al., 2013). Only two 
studies reported cognitive behavioural techniques in detail (Freeman et al., 2018; 
Botella et al., 2016). Freeman and colleagues’ (2018) automated therapy set up a series 
of behavioural experiments facilitating cognitive change. Beliefs about heights were 
identified and rated at the beginning of the treatment and again at the end to track 
progress and change.   
Botella and colleagues’ (2016) augmented reality treatment for small animal 
differed from the other studies in the technology used and therapist involvement as 
outlined previously. The treatment was based on a single session, intensive treatment of 
spider phobia and involved ‘reinforced practice’ and ‘cognitive challenging’ (Öst, 
Salkovskis and Hellström’s, 1991; Öst, 1989) However, the authors did not expand 
upon how cognitions were identified and challenged.  
Homework 
Only three of the studies in the review set homework tasks for participants. Rus-
Calafell and colleagues (2013) taught participants to use diaphragmatic breathing and 
instructed them to practice between sessions. At the beginning of therapy, participants 
were also asked to purchase a plane ticket to use 15 days after the end of treatment, a 
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homework task also set by Tortella-Feliu et al. (2011). The purpose of this was to 
improve motivation and encourage completion of the intervention. Botella and 
colleagues (2016) also set homework following the intervention, encouraging 
participants to continue exposing themselves to feared stimuli. No further instructions 
were provided on how or when this should be done.  
Maximising exposure 
The therapeutic techniques recommended by Craske et al. (2014) to maximise 
outcomes based on the inhibitory learning model of exposure were reported in a number 
of the studies. The most frequently used was encouragement to drop safety seeking 
behaviours, such as avoidance or looking away. Eight of the studies asked participants 
to refrain from using these behaviours (Minns et al., 2019; Gujjar et al., 2019; Freeman 
et al., 2018; Lima et al., 2018; Meyerbröker et al., 2018; Jaquart et al., 2017; Shiban et 
al., 2015; Tart et al., 2013 & Quervain et al., 2011). Most of the authors provided 
minimal information on how participants were encouraged to drop safety behaviours, so 
it was assumed that psychoeducation was the primary tool to facilitate insight. Quervain 
et al. (2011) and Freeman et al. (2018) were the only researchers to mention cognitive 
safety behaviours, for example, participants telling themselves the scenario isn’t real. 
This type of safety behaviour threatens presence in virtual reality and is difficult to 
monitor. Freeman and colleagues (2018) provided the most detail on how they 
addressed safety behaviours as the treatment was automated and therefore the same for 
all participants, for example, “Many people try to deal with their fear by using 
defences…closing your eyes when you’re up high and not looking down, repeating a 
comforting phrase to yourself, taking off your shoes…”. They also used a series of tasks 
such as lowering a barrier and playing a xylophone over the edge of a balcony to place 
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their participants in situations that forced them to abandon behaviours they would 
normally rely upon. 
Freeman’s automated therapy also utilised two other techniques recommended 
by Craske and colleagues: expectancy violation and variability. To violate expectancy, a 
mismatch between what is expected, and the actual outcome needs to be large so that 
new learning can take place. In the automated treatment, participants were asked to 
complete tasks that were more challenging than could be achieved in vivo, such as 
rescuing a cat from the tree. Feelings of safety were rated rather than distress, which is 
supported by the evidence that within-session fear reduction does not predict outcomes 
(Baker et al., 2010). New learning about the feared stimulus was anticipated in the 
remaining thirteen studies that detailed the virtual reality treatment and used hierarchy 
exposure models, but this was not counted as expectancy violation. This is because 
progression was based on SUDS ratings or time elapsing and the target was fear 
reduction, not what needed to be learnt about the stimulus. Freeman et al. (2018) was 
also the only study to use variability, by introducing tasks of varying difficulty at 
random. The other studies used scenarios of increasing difficulty, except for Michalszyn 
et al. (2010) who presented a single level of difficulty.  
Shiban et al. (2015) explicitly investigated the effect of multiple contexts on a 
virtual reality treatment for spider phobia. This involved changing the context of the 
exposure to improve generalisability. Shiban and colleagues conducted a four-arm trial, 
changing the appearance of the stimulus (virtual spider) and the context of exposure 
(virtual basement). The colour of the spiders was changed to alter their appearance and 
the wallpaper, flooring and lighting were altered in the basement. Whilst Shiban et al. 
(2015) were the only authors to state multiple contexts as a construct, most of the other 
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studies in this review used similar methods. Five studies used the same environment but 
changed the stimulus. Gujjar et al. (2019) kept participants sat in a dentist’s chair 
throughout but changed auditory content and the dentist’s behaviour. Lima et al. (2018) 
increased the intensity of the weather, moving from a still day to thunder and lightning, 
similar to Meyerbröker et al. (2011) who changed weather conditions to affect 
turbulence on an aircraft. The other two studies changed the proximity and movements 
of virtual spiders and cockroaches to increase anxiety (Minns et al., 2019; Botella et al., 
2016). Seven studies used multiple environments within the scenario. Five of these 
studies used fear heights treatments that progressed participants through a series of 
floors, lifts, bridges and balconies (Freeman et al., 2018; Meyerbröker et al., 2018; 
Jaquart et al., 2017; Tart et al., 2013 & Quervain et al., 2011). The fear of flying 
scenarios used by Rus-Calafell et al. (2013) and Tortella-Feliu et al. (2011) used three 
different contexts: a bedroom, a terminal and an aircraft.   
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Table 4. Therapeutic components of virtual reality treatments 
Study No. of 
sessions 
Time in VR 
Total or Mean 
(M)  
Psycho-
education 
CBT 
techniques 
Maximising 
exposure  
Therapist 
active 
during VR  
Homework 
Minns et al. (2019) 1 30 mins   × DSB × × 
Gujjar et al. (2019) 1 40.6 mins (M) × × DSB × × 
Freeman et al. (2018) 6 124.4 mins (M)   DSB, MC, 
Var, EV 
 (virtual) × 
Lima et al. (2018) 1 1 hour × × DSB × × 
Meyerbröker et al. (2018) 3 2.5 hours   × DSB × × 
Jaquart et al. (2017) 1 30 mins    DSB × × 
Botella et al. (2016) 1 3 hours NR   ×  Y 
Triscari et al. (2015) 16 6 hours    × NR NR 
Shiban et al. (2015) 1 20 mins NR × DSB, MC × × 
Moldovan & David (2014) 1 1.5 hours    × × × 
Abbreviations: NR, not reported; DSB, dropping safety behaviours; MC, multiple contexts; Var, variability; EV, expectancy violation 
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Table 4 (continued). 
Tart et al. (2013) 2 1 hour   DSB  N 
Rus-Calafell et al. (2013) 6 6 – 7.5 hours   ×  Y 
Meyerbröker et al. (2012) 4 4 hours  × × × × 
Tortella-Feliu et al. (2011) 1 NR   ×  Y 
Quervain et al. (2011) 3 1 hour  × DSB  × 
Michalszyn et al. (2010) 8 9.5 hours   × NR × 
Abbreviations: NR, not reported; DSB, dropping safety behaviours; MC, multiple contexts; Var, variability; EV, expectancy violation
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Key findings 
Virtual reality treatments were effective at reducing scores on the primary 
outcomes in all the studies. The biggest effects were found when virtual reality was 
compared to non-active controls such as waiting lists and informational pamphlets 
(Minns et al., 2019; Gujjar et al., 2019; Freeman et al., 2018; Lima et al., 2018; Triscari 
et al., 2015). These results were also reflected in the within group effect sizes of studies 
that used multiple virtual reality conditions or active controls. There was no statistically 
significant difference between virtual reality, in vivo, and imaginal exposure. It was 
therefore deemed an effective and viable treatment alternative (Botella et al., 2016; Rus-
Calafell et al., 2013; Michalszyn et al., 2010).  
External augmentations to virtual reality could only be evaluated for drug 
treatments and physical exercise. The other studies used virtual reality as the 
experimental condition which meant augmentations such as cognitive behavioural 
therapy and relaxation were used in all groups. Propanalol was more effective at 
reducing anxiety scores in virtual reality than placebo (Meyerbröker et al., 2018) as 
were Glucocorticoids (Quervain et al., 2011). Neither Yohimbine Hydrochloride nor D-
Cycloserine provided any additional benefit to virtual reality exposure treatments (Tart 
et al., 2013; Meyerbröker et al., 2012). Physical exercise completed for 20 minutes prior 
to virtual reality for fear of heights did not provide any additional benefit at post-test 
scores one week later (Jaquart et al., 2017). However, the timing of the exercise 
augmentation was highlighted by the authors as a possible reason for null findings. 
Whether virtual reality was therapist or self-administered was not found to have an 
effect (Tortella-Feliu et al., 2011). However, minimal information was provided on 
therapist involvement during virtual reality and all groups received therapist input at the 
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start and finish of the intervention. The use of multiple contexts had a positive effect on 
self-reported spider phobia scores in the short term, but this reduced over time. Using 
multiple stimuli during exposure was also beneficial in the short term and was 
maintained at follow up (Shiban et al., 2015). There was substantial variation in the 
content of treatments including the number of sessions and the use of additional 
components external to VR. Therefore, the treatments in this review could not be 
directly compared so the most effective components of treatment are yet to be 
established.   
Discussion 
The purpose of this review was to evaluate the content of current virtual reality 
treatments for specific phobias. Randomised controlled trials, published in the last ten 
years that used virtual reality as a component of treatment, were reviewed. The primary 
treatment targets of the trials were to reduce self-reported fear and avoidance of phobic 
stimuli.  
Approximately half of the studies discussed investigated the efficacy of virtual 
reality in comparison to non-virtual control conditions. The remaining studies used 
augmentations external to or within the virtual environment. It is widely acknowledged 
that immersive virtual reality is as effective as in vivo for the treatment of phobias (Carl 
et al., 2019). However, this review highlighted a paucity of research in the development 
and advancement of virtual reality as a stand-alone treatment and a lack of detailed 
reporting on treatment content. It seems that researchers have focused more on the 
believability and immersion of virtual environments over and above therapeutic content, 
directing future research to investigate new technology as opposed to treatment 
techniques. This is also reflected in the poor methodological quality and relatively small 
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sample sizes of many of the studies reviewed. Pilot trials of new VR systems have 
dominated the research and larger clinical trials (phase II+) are yet to be conducted. 
Arguably, translational research is the next step for virtual reality treatments for 
phobias.  Researchers should now investigate the full potential of virtual reality, how it 
can be used to enhance treatments and how it can target unmet clinical needs.  
Notably, only a few studies utilised the technology available to create novel 
environments. Most authors used it to replicate the real world or as controlled 
conditions to test the effect of medication. This is despite significant advancement in 
virtual reality technology, so it is important to consider why this is the case. 
Importantly, only in recent years have systems become affordable and commercially 
available. As a result, research teams no longer require a large footprint or specialist 
computers to run clinical trials. The headsets are now portable and some companies, 
such as HTC, have released wireless systems but the construction and design of virtual 
environments continues to be expensive. They take time to build and require specific 
skills in computer science, which is economically limiting. This undoubtedly affects the 
motivation to test components of virtual reality treatments when pre and post effect 
sizes are already large and equivalent to in vivo exposure. It also encourages research 
teams to re-use existing scenarios and may explain why so many studies have targeted 
augmentations external to virtual reality. Indeed, two studies used the same Virtually 
Better® software for fear of storms and fear of heights (Lima et al., 2018; Jaquart et al., 
2017), and two used the same Virtual Flight® scenario (Rus-Calafell et al., 2013; 
Tortella-Feliu et al., 2011).  
Importantly, using virtual reality simply as an alternative to in vivo overlooks 
one of its main potential future advantages, to create scenarios that are unachievable in 
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the real world. For example, Freeman and colleagues (2018) are the first to use a fully 
automated treatment that used avatars to create a virtual therapist or ‘coach’. Only a few 
studies in the review used a therapist during the virtual reality component and not all 
were clinically trained so there is an evident need to integrate and standardise how 
treatment is delivered. Creating avatars that respond to the user and are pre-programmed 
to provide evidence-based therapies is a unique and exciting application of this 
technology. Many people with phobias don’t seek treatment (Wolitsky-Taylor, 
Horowitz, Powers & Telch, 2008) and those that do often wait for years after the phobia 
developed (Le Beau et al., 2010). Therefore, automation could improve help-seeking for 
phobias by normalising treatments and increasing accessibility. Indeed, participants who 
were given the choice between virtual reality and in vivo exposure reported a preference 
for the former, suggesting virtual treatments may be effective for clinical populations 
that are less likely to seek help (Curtis, 1998). The use of virtual reality in the treatment 
of psychosis supports this notion as this is a difficult to reach population yet VR is 
considered acceptable and safe to use (for a review see Rus-Calafell, Garety, Sason, 
Craig & Valmaggia, 2018).    
The potential limitation of virtual environments that do not mirror the real world 
is that immersion and generalizability may be affected. It is also possible that cognitive 
safety behaviours, for example, telling themselves it isn’t real, are more prevalent. 
Cognitive avoidance is particularly difficult to control in virtual reality as it requires 
self-monitoring and disclosure. In addition, verbal communication during the scenario 
has the unwanted effect of breaking presence that could increase avoidance. However, 
careful or ‘judicious’ use of safety behaviours early in therapy can increase engagement 
and facilitate progress if used correctly (Rachman, Radomsky & Shafran, 2008). 
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Therefore, if the exposure is sufficiently challenging, some cognitive safety behaviours 
may be beneficial and could explain the lower rates of drop out reported in virtual 
reality treatments in comparison to in vivo (Garcia-Palacios et al., 2007).  
Few studies compared virtual reality treatments, tested individual treatment 
components or created novel environments. Trials of medication augmentations were 
the only studies to compare the same treatments, but virtual reality was used to create 
experimental conditions, so the treatments were purely exposure based. Shiban and 
colleagues (2015) were the only researchers to compare treatment components and to 
investigate mechanisms of change but none of the studies tested treatment mediators or 
moderators. This study used virtual reality to manipulate the targeted mechanism by 
changing the appearance and context of virtual spiders. The trial investigated whether 
different combinations of single or multiple context exposure was superior or if there 
was no additional benefit. The results indicated that using multiple contexts for 
exposure reduces fear renewal in the short term but using multiple stimuli is beneficial 
across time points. This finding is informative as most studies used multiple contexts 
within their scenarios but didn’t identify or test these as potential mediators.  
 Only one study made adaptations to the virtual environment that could not be 
safely or easily achieved in vivo, such as rescuing a cat from a tree (Freeman et al., 
2018). In this study, participants were presented with novel, challenging scenarios that 
required them to drop safety behaviours and approach the feared stimulus, increasing 
opportunity for new learning. The effect sizes achieved were larger and greater than 
expected for face to face therapy. Most of the studies did encourage participants to drop 
safety behaviours but this was often in the context of habituation and involved 
approaching feared stimuli or limiting avoidance. Given the evidence that fear renewal 
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is common in the treatment of phobias, it is surprising that alterative models of exposure 
are not being applied. Virtual reality provides the opportunity to test out augmentations 
and is an obvious platform to apply the recommendations made by Craske et al. (2014) 
based on the inhibitory learning model of exposure. However, it is likely that the focus 
on fear reduction and lack of follow up data with measures capturing cognitive change, 
have led to minimal interest in developing treatments in this way.  
Exposure models 
In line with the finding that most studies used virtual reality to replicate in vivo, 
nearly all studies used a hierarchical model of exposure. The exception was Freeman et 
al., (2018) who set up a series of behavioural experiments. Virtual environments based 
on hierarchical exposure increase the intensity of the stimuli in stages and habituate 
participants until their anxiety reduces or a specified amount of time has elapsed. These 
environments were designed to be completed in stages (single or multiple sessions) and 
become progressively more challenging. The model is based on the principle that 
exposure to feared scenarios reduces anxiety as the predicted danger associated with the 
stimulus does not occur. Given that fear renewal is common in phobias and habituation 
is considered one of many mechanisms involved in extinction, it is surprising that 
hierarchical exposure continues to be the primary approach in virtual reality treatments.  
Despite most studies using similar models of exposure, there was variation in the 
length of treatment, therapist involvement, and the method of progression. The overall 
time spent in virtual reality ranged from 20 minutes to 7.5 hours, yet this was not 
reflected in the effect sizes which were all medium to large. In fact, large effect sizes 
were found in both one session and multiple session treatments on self-report phobia 
measures. Notably, none of the studies tested the effect of number of sessions and 
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several of the longer treatments used additional components making this difficult to 
analyse. It is unclear why there is so much variation in the number of sessions provided 
as many trials of virtual reality as a treatment for phobias were published before the 
studies in this review. It seems that virtual reality is presented as a tool to be used as 
part of therapy rather than as a self-contained treatment. Freeman and colleagues’ 
(2018) automated intervention is unique in this regard but it also threatens the role of 
real therapists, which other researchers may find challenging. There is also variation in 
how involved the scenario is and whether participants were active or passive within the 
environment. This partly relates to the age of the technology and the design of the 
system, but it is an important aspect of the exposure and will have different effects on 
learning.  
 As expected, similar virtual reality technology was used in most of the studies, 
with the exception of Michalszyn et al. (2010) which was the oldest study in the review. 
This supported the limit applied to publication date in the inclusion criteria and 
highlights the importance of reviewing the research as the technology develops. Head 
mounted displays are now being used by most research teams, with only the occasional 
use of CAVE automatic virtual environments. Only one study used augmented reality 
for small animal phobia, which is not surprising. These systems use a combination of in 
vivo and virtual feedback, combining the two environments. Hence, they are only 
suitable for certain phobias and may be less cost effective in the long term as it still 
requires components of in vivo exposure. In contrast, immersive head mounted displays 
create a self-contained world that rely solely on the technology.    
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Limitations of the review  
There are several limitations to this review. Firstly, only randomised controlled 
trials were included. This meant case reports and protocols were not discussed, which 
may have added greater variety in treatment techniques (though less evidence of 
efficacy).  
 A second limitation is the focus on specific phobias. As one of the earliest uses 
for virtual reality in mental health care, the area has been reasonably well researched. 
This could have led to more experimental uses of the technology, but it seems that there 
has been less impetus to develop new applications as the treatments are well 
established. Expanding the search criteria to other presentations may provide a different 
picture of treatment techniques applied in VR.  
 Thirdly, most of the studies reviewed had small sample sizes and did not directly 
compare treatments of the same phobia. Some researchers even compared treatments for 
multiple different phobias within the same study, further reducing power and diluting 
findings. This makes it difficult to directly link treatment differences to outcomes. The 
variation in methodological quality was also an issue as there was large variation in 
recruitment strategies, study design and the reporting of findings. Until larger, high 
quality trials are conducted, and virtual reality is prepared for clinical use, treatments for 
specific subtypes of phobia are unlikely to be compared. Without direct comparisons, 
treatment mediators and moderators cannot be tested, limiting future progress and the 
development of new treatments.    
 Finally, the review was limited to studies published within the last ten years. 
This was decided upon to restrict large variation in the technology being used but 
relevant studies may have been excluded. As the predominate model of exposure in 
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virtual reality appears unchanged since early studies in the area, the review does not 
cover information about how these were developed. The use of existing software within 
trials also presents a limitation as the primary papers testing these environments may 
not have been included.    
Future directions 
One of the key findings of this review is that few researchers are investigating 
the content of virtual reality treatments for phobias or seeking to utilise the technology 
to its full capacity. Studies like Shiban et al. (2015) that compare multiple virtual reality 
treatments for the same phobia should be one important format for research moving 
forward. Virtual reality is an established treatment, the effect sizes are large, and it is 
equivalent to in vivo exposure. These treatments are now being integrated into clinical 
services so focus should turn to augmentations and treatment moderators and mediators 
to understand the mechanism of effects and to use that knowledge to increase efficacy 
(Dunn et al., 2015). Many of the studies in this review used additional components that 
were external to virtual reality, but these were not compared to adequate controls. These 
components need to be properly tested to understand whether they provide any 
additional benefit. Likewise, the number of sessions, time spent in virtual reality, and 
the model of exposure needs to be evaluated more thoroughly. One explanation for the 
large variation in content is the lack of standardised reporting of virtual reality studies. 
This makes it difficult for researchers to thoroughly consult the literature before testing 
new interventions. One solution would be the development of a checklist to guide 
researchers in the reporting of clinical trials using virtual reality. This would both add 
clarity to the evidence base and help direct researchers on study design and the 
development of future interventions.  
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Virtual reality technology has advanced, and it is now an accessible and 
affordable platform for health care. Consequently, the content and the methods of 
evaluation need to modernise if we are to maximise the potential of virtual reality in 
health care.  
Conclusion 
In summary, this review found that most virtual reality treatments for specific 
phobias use hierarchy exposure models. This is the same approach that was used in the 
early VR treatment studies despite significant advancement in virtual reality software 
and hardware. Only a few studies utilised virtual reality to create scenarios that can’t be 
replicated in the real world, but the majority used it as a digital version of in vivo 
exposure. Differences in the components of virtual reality were found across studies 
but, notably, only one study investigated treatment mechanisms. The potential of virtual 
reality as a platform to deliver treatments that target new learning and fear extinction is 
yet to be fully explored. However, despite variation in the number of sessions and the 
use of additional therapeutic components external to virtual reality, the effect sizes for 
pre to post treatment were medium to large and comparable to in vivo exposure. This 
supports the current literature on virtual reality as a treatment for specific phobias. 
Future research should seek to use virtual reality beyond it’s obvious use as a replica of 
reality and design scenarios that make further use of its capabilities. It is recommended 
that individual treatment components are tested, and the comparison of multiple virtual 
reality treatments is prioritized.  
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Chapter 2: Empirical study 
 
Deepening extinction in a virtual reality treatment for fear of heights 
67 
 
Abstract 
Background: Clinical trials indicate that virtual reality (VR) treatments for 
specific phobias are efficacious but how can new learning be maximised? The interest 
of the current study is physiological arousal as it is associated with fear responses but 
there is discordance between objective and subjective measures both in vivo and in 
virtual reality.  
Aim: The aim of the study was to investigate whether increasing physiological 
arousal using exercise increases the efficacy of an automated virtual reality treatment 
for fear of heights. Secondary aims were to test potential predictors of cognitive change 
and mediation of manipulation effects. 
Method: A randomised controlled clinical-experimental test was conducted. 60 
individuals with a fear of heights were randomised to either the VR treatment alone or 
with increased physiological arousal. Participants with a fear of heights were recruited 
via radio and public advertisements in Oxfordshire, UK, were aged between 18-65 years 
old, and scored >45 on the anxiety subscale and >8 on the avoidance subscale of the 
Acrophobia Questionnaire. The primary outcome was degree of conviction in the 
phobic threat belief, which was measured before and directly after treatment. The 
manipulation group completed 2-3 minutes of cycling at 80% of their maximum heart 
rate. To test predictors of cognitive change anxiety, mood, safety behaviours and risk 
aversion, were assessed. To test mediation of the manipulation, self-efficacy and 
subjective distress were assessed. Neither participant nor researcher was blind to group 
allocation.  
 Results: There were no missing data for the primary outcome in the study. 
Participants spent an average of 30 minutes receiving the VR treatment. Physiological 
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arousal was significantly higher in the manipulation group compared to the control 
group, (p<0.0001), (d=2.9). There was no significant difference between the two groups 
in degree of conviction in the fear of heights threat belief, (p=0.56), (d=0.1). Both 
groups showed significant reductions in fear of heights threat beliefs after the VR 
treatment (p<0.0001), (d=1.0). Self-reported distress, anxiety sensitivity, risk aversion, 
use of safety behaviours, and mood did not predict cognitive change.  
 Conclusion: An increase in physiological arousal achieved via exercise does not 
enhance cognitive change in beliefs about the feared stimuli in virtual reality treatment. 
Regardless of the augmentation, participants reported a significant reduction in belief 
conviction after a single 30-minute session, but predictors of change were not identified. 
Limitations include the short-term nature of the test, the absence of blinding, and lack of 
follow up data.  
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Introduction 
Virtual reality (VR) treatments for specific phobias are effective and produce 
similar results as face to face therapies. However, VR has yet to be used to its full 
potential despite substantial developments in the technology. One approach is to update 
the methods of exposure from outdated habituation models to inhibitory learning 
approaches and to investigate augmentations that may enhance treatment. Virtual reality 
provides both the experimental conditions to examine if and how treatments for specific 
phobias can be improved, and a means of developing standalone interventions that can 
be used in a range of clinical settings. If automated, these treatments have the potential 
to be widely disseminated and to address unmet clinical need without requiring 
specialist expertise. Therefore, it is important to consider how these treatments work 
and if they can be enhanced if the capabilities of VR are to be maximised.   
Virtual reality  
Psychological therapy delivered via virtual reality is becoming part of healthcare 
provision. Headsets are now affordable, and technology is no longer limited to specialist 
laboratories, making it possible to integrate into clinical settings (Jerden, Grindle, 
Woerden & Boulos, 2018; Freeman et al., 2017). Current virtual reality systems consist 
of head mounted displays with stereoscopic vision and advanced tracking technology to 
enable the simulations to rapidly update on the basis of a user’s movements. The 
technology has developed substantially in the last few years, but virtual reality has been 
used in the treatment of fear of heights since the 1990s (Rothbaum, et al., 1995a; 
Rothbaum et al., 1995b) and has since developed an evidence base (Coelho et al., 2009; 
Emmelkamp et al., 2001; Meyerbroker & Emmelkamp, 2010). Research also supports 
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its use in the treatment of conditions such as post-traumatic stress disorder, substance 
misuse, eating disorders, and paranoia (for review see Freeman at al., 2017).   
One reason that VR has been used for the treatment of phobias for so many 
years is because feared stimuli can be easily generated in the virtual world and 
introduced to the user without the risk of actual harm. It is also possible to design 
scenarios that are somewhat impractical to use in vivo or unachievable in the real world. 
However, it is the feeling of immersion in VR that makes it particularly powerful, a 
phenomenon known as ‘presence’. Slater (2009) describes presence as a combination of 
place illusion and plausibility illusion. Place illusion refers to the virtual environment 
simulating what you would expect to experience in reality, for example, when you look 
around, the environment moves with you and replicates the sensory feedback of the real 
world. This is achieved by accurate motion trackers that minimise tracking latency and 
create fully immersive systems. Plausibility illusion reflects how well the virtual 
environment responds to the user, for example, if they step towards an avatar and the 
avatar steps back, the environment is reactive to user initiated movements. In exposure-
based environments, presence allows users to respond as if faced with a feared scenario 
in the real world. As previously mentioned, Rothbaum and colleagues first did this in 
the 1990s by creating virtual scenarios of high places such as, buildings and stairwells 
that allowed people with a fear of heights to be exposed to phobic stimuli via graded 
hierarchies. Many studies have since followed yet little has changed as to how these 
treatments are delivered. The primary focus for researchers continues to be how 
believable and immersive the environment is to the user rather than how the treatment 
content can be improved. However, in a recent study by Freeman et al. (2018) an 
automated treatment of fear of heights was successfully trialled against a control group 
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with good effect. Unlike previous studies, this treatment used a ‘virtual coach’ to guide 
users through a series of tasks in the format of behavioural experiments, which differs 
from the habituation models featured in previous studies. This was a VR cognitive 
therapy for fear of heights that if disseminated into clinical settings, has the potential to 
improve access to psychological therapies for people with specific phobias as it is fully 
automated. 
Fear of heights 
Specific phobias are a common disorder and have a lifetime prevalence of 
12.5% and a 12-month prevalence of 9.1% (The US National Comorbidity Survey 
Replication, NCS-R, 2004). Acrophobia or ‘fear of heights’ is the second most 
commonly reported phobia (Curtis, 1998) and has a cross-national prevalence of 2.8-
5.3% (Wardenaar et al., 2017; Le Beau et al., 2010). Fear of heights is characterised by 
a marked fear and avoidance of high places, and a presence of phobic beliefs about 
falling and how this is likely to occur. These include the structure collapsing, losing 
balance and jumping over the edge. Beliefs about feared stimuli are a feature of specific 
phobias more generally (Thorpe & Salkovskis, 1995) and most people have more than 
one fear (Curtis, 1998). It is therefore common for people with a fear of heights to 
report multiple situations that could lead them to fall. They are also more likely to 
report internal cues of anxiety and to interpret ambiguous bodily sensations threatening 
(Coelho & Wallis, 2010; Davey, Menzies & Gallardo, 1997). Consequently, many 
people avoid high places and few seek treatment despite an established evidence base 
that supports the use of psychological therapies in the treatment of fear of heights.  
Exposure techniques are the primary component of most treatments for specific 
phobias. They work by exposing the phobic person to the feared stimulus to provide 
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new information and, therefore, new learning that contradicts phobic beliefs and reduces 
fear. Often, this is achieved via habituation which requires the person to face the feared 
situation or object until their self-reported anxiety decreases. This continues to be used 
by many clinicians and to date, has been the primary approach in virtual reality 
treatments for phobias. Habituation is the hallmark of the emotional processing theory 
of exposure (Foa & Kozak, 1986; Foa & McNally, 1996) and is frequently achieved by 
completing graded hierarchies whereby the person progresses through scenarios of 
increasing difficulty. Progression is either based on anxiety reduction or waiting for a 
period of time to elapse. However, the emphasis on habituation has been challenged as 
within and between session fear reduction does not predict outcomes as suggested 
(Baker et al., 2010; Craske et al., 2008). Furthermore, fear renewal is common, and 
treatment does not work for everyone. Craske and colleagues’ ‘Inhibitory Learning 
Model’ of exposure consolidates the literature on fear extinction and recommends 
strategies to optimize exposure and improve outcomes (Craske, Kircanski, Zelikowsky, 
Mystkowski, Chowdhury & Baker, 2008). These recommendations suggest that 
habituation is only a partial treatment mechanism and that multiple different 
mechanisms are required to achieve lasting therapeutic change.  
Inhibitory learning  
Evidence for the inhibitory learning model has accumulated (for a review see 
Jacoby & Abramowitz, 2016). The theory outlines possible mechanisms of exposure 
and the role of inhibitory learning, which is central to fear extinction. Inhibitory 
learning refers to new (inhibitory) associations with the feared stimulus that are created 
during exposure. This means that the phobic person’s original association with the 
stimulus is not extinguished but remains intact and a new, secondary non-fearful 
73 
 
association is created that inhibits the original. However, the latter is vulnerable to re-
activation which can occur for a number of reasons; a new context (e.g. patient exposed 
to spider in a laboratory encounters one at home), re-traumatization (e.g. patient with a 
phobia of dogs is bitten) or time elapsed since exposure (e.g. patient exposed to heights 
does not re-expose themselves to high places and the fear returns), (Craske et al., 2008; 
Craske, Treanor, Conway, Zbozinek & Vervliet, 2014; Craske, 2015). Furthermore, 
people with anxiety disorders have deficits in inhibitory learning, which means they 
find it more difficult to inhibit the original phobic association, increasing the likelihood 
of fear renewal (Lissek et al., 2005; Liao & Craske, 2013).   
Clinical recommendations made by Craske and colleagues to maximise exposure 
outcomes include violating expectancy, increasing variability of the exposure (in 
contrast to graded hierarchies), using multiple contexts, removing safety behaviours, 
combining phobic cues (deepening extinction), occasional reinforced extinction, and 
incorporating retrieval cues. The application of these strategies to exposure treatments 
requires research (Craske, 2015) but the evidence base is growing. Mixed results have 
been found for multiple context exposure but there are large variations in study design. 
In a series of conditioning studies, Neumann (2006) found 3-context exposure reduced 
fear renewal compared to a single context session, but this wasn’t replicated in a later 
study (Neumann, Lipp & Cory, 2007). However, varying context by light level was 
effective, in particular when similar to the acquisition context (Balooch & Neumann, 
2011). These results were from non-clinical populations, but similar results were found 
with spider phobic participants during in vivo exposure (Bandarian-Balooch, Neumann 
& Barosch, 2015). Likewise, Shiban, Schelhorn, Pauli and Mühlberger (2015) used 
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virtual reality to manipulate treatment context and found that changing the stimulus was 
more effective than changing the environment.  
Virtual reality provides an ideal platform to investigate these strategies as 
environments and stimuli can be manipulated in experimental conditions, and 
augmentations can be compared. Multiple context exposure has been used effectively 
using computer-generated spiders on a flat screen (Vansteenwagen et al., 2007) and in 
immersive virtual reality (Shiban, Pauli & Mühlberger, 2013). However, most studies 
have used virtual reality to mirror in vivo exposure. The full potential of this technology 
has not been explored, and there is a paucity of research comparing different virtual 
reality treatments. As habituation is only a partial mechanism of exposure (Rowe & 
Craske, 2008), it is surprising that treatments have not been further developed. Notably, 
the therapeutic content of virtual reality treatments for fear of heights has barely 
changed since the 1990s, with the exception of Freeman et al’s. (2018) automated 
treatment. This intervention incorporated many of the recommendations made by 
Craske et al. (2008; 2015) and reported large effect sizes at pre and post treatment 
(d=2.0) that were maintained at follow up. However, similar to many treatment studies 
using virtual reality, the automated treatment was compared to a non-treatment control 
so it is unclear whether particular elements of the intervention were more beneficial 
than others. This was not aim of Freeman’s study, which set out to test whether 
automating therapy was effective but it does raise important questions about how these 
treatments work and what should be included in future scenarios. As the automated 
therapy was efficacious, further investigation into individual treatment components and 
possible augmentations is warranted to maximise outcomes and refine treatment 
content. 
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Augmentations to exposure 
The study of augmentations to exposure therapies is not limited to the 
recommendations outlined by Craske and colleagues. Indeed, researchers have 
investigated a range of augmentations to improve learning consolidation during and 
after psychological treatment for exposure therapies. For example, pharmacological 
augmentations such as, D-cycloserine (Tart et al., 2013), Yohimbine Hydrocholride 
(Meyerbröker et al., 2018 & 2012), Propanalol (Meyerbröker et al., 2018) and 
Glucocorticoids (Quervain et al., 2011) have been investigated by a number of 
researchers for their effect on learning and fear extinction. However, these produced 
mixed results; propanalol and glucorticoids were both found to reduce anxiety in virtual 
reality but D-cyloserine and Hydrocholride did not provide any additional benefit.  
There is also evidence that physical exercise improves learning consolidation 
following exposure (Roquet & Monfils., 2018) but many of these studies focused on 
rodent samples with only a few using human participants. In a recent study by Jaquart et 
al. (2017) participants were asked to complete 20 minutes of aerobic exercise prior to 
exposure, which was predicted to upregulate the brain derived neurotrophic factor 
(BDNF) and enhance learning consolidation. BDNF is thought to be lower in anxious 
populations and is believed to reduce subjective fear and fear renewal, but the authors 
found no difference between conditions. Notably, participants in this study returned to 
their resting heart rate before starting exposure, which differed from a study of similar 
design by Powers et al. (2015). Powers and colleagues sought to enhance prolonged 
exposure for PTSD by also increasing BDNF but importantly, there was only 5 minutes 
before starting exposure compared to 20 minutes in Jaquart’s study. Unlike Jaquart and 
colleagues, acute exercise was found to have a positive augmentation effect. One 
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explanation for these findings is that physiological arousal during exposure was higher 
in the Powers et al. (2015) study. As a result, the exposure may have been more intense 
and aversive than the Jaquart et al. (2017) study, providing additional opportunities for 
new learning about the feared stimulus.  
Physiological arousal is a characteristic of fear and anxiety. In specific phobias, 
the relationship between arousal and subjective anxiety has been examined, but these 
are not always synchronous, and one does not necessarily predict the other 
(Emmelkamp & Felten, 1985; Taylor, 1977). Similar findings have been reported in 
virtual reality as skin conductance was associated with self-reported anxiety, but there 
was no change in heart rate (Wilhelm, Pflatz, Gross, Mauss, Kim, Wiederhold, 2005). 
However, the link between internal and external cues of anxiety is more relevant in 
specific phobias than the literature would suggest (Craske, 1991). Notably, Coelho and 
Wallis (2010), and Davey, Menzies and Gallardo (1997) found that people with a fear of 
heights often misinterpret internal cues of anxiety and appraise physiological arousal as 
threatening. This indicates that increased arousal heightens the perceived risk of falling 
and increases fear. Most of the research on physiological arousal is observational and 
uses virtual reality to investigate fear responses between controls and phobics 
(Wiederhold, Jang, Kim, Wiederhold, 2002). Few studies have directly manipulated 
arousal, and none have tested effects on self-reported distress or phobic beliefs.  
Aerobic exercise is one method of inducing physiological arousal that was used 
by Jaquart et al. (2017) and Powers et al. (2015) but in these studies, physiological 
arousal was a by-product of the manipulation and not the primary interest. In other areas 
of research, acute exercise has been used successfully to reduce anxiety sensitivity i.e. 
fear of the internal sensations of anxiety (Sabourin, Stewart, Watt & Krigolson, 2015; 
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Broman-Fulks & Storey, 2008; Smits, Berry, Rosenfield, Powers, Behar & Otto, 2008; 
Broman-Fulks, Berman & Webster, 2004), and for the treatment of panic disorder 
(Broocks et al., 1998). Anxiety sensitivity is a risk factor for anxiety disorders (Taylor, 
1999) and predicts fearfulness (Reiss, Peterson, Gursky & McNally, 1986). 
Furthermore, Taylor, Koch and McNally (1992) found anxiety sensitivity to be higher 
in most anxiety disorders compared to controls, except for simple phobia. However, this 
study did not include people with a fear of heights who are known to find anxious 
arousal aversive.  
There are mixed results for the effect of exercise on exposure therapy, 
specifically anxiety disorders (for a review see Jayakody, Gunadasa & Hosker, 2012) 
but some positive effects have been reported. Herring, Hallgren & Campbell (2017) 
found that completing 30 minutes of aerobic exercise improved worry and state anxiety 
whereas Zeng, Pope, Lee & Gao (2018) found a reduction in depression and anxiety 
scores following VR based exercise. One explanation for these findings is that the effect 
of exercise is moderated by negative appraisals of physiological arousal and that 
exercising prior to or during treatment exposes the person to interoceptive cues of 
anxiety. This may be particularly salient for panic disorder. Alternatively, other 
mediating factors may explain these results such as increased self-efficacy. Evidence 
shows that exercise increases feelings of self-efficacy and improves positive affect 
(Reed & Ones, 2006; McAuley, Blissmer, Katula & Duncan, 1998; Rudolph & Butki, 
1998). If self-efficacy does improve following a short period of exercise, phobics may 
feel more able to engage in challenging situations during exposure, increasing the 
opportunity for new learning and cognitive change.  
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Identifying augmentations is one method of improving treatment outcomes for 
specific phobias that can be investigated using to virtual reality technology. However, it 
is also important to consider who is likely to benefit from these treatments and whether 
specific components are more beneficial to particular groups of people. This is 
particularly relevant as automated treatments will need to address individual differences 
and overcome the absence of person centred content found in face to face therapy.  
Predictors of treatment outcomes 
Surprisingly, the literature on predictors of treatment outcome in specific 
phobias is inconclusive (Eskildsen, Hougaard & Rosenberg, 2010; Hellström & Ost, 
1996). There is some evidence that limited coping skills and a negative cognitive style 
lead to poorer outcomes (Trumpft, Margraf, Vriends, Meyer & Becker, 2010), and that 
positive mental health predicts symptom remission (Tesimann, Brailovska, Totzeck, 
Wannemüller & Margraf, 2018) but these are relatively broad constructs. Muris, Meyer 
& Merckelback (1998) found a strong association between state and trait anxiety with 
treatment outcomes in spider phobics, with high trait anxiety negatively affecting 
outcomes following behavioural therapy. In a 5 year follow up study, spider phobics 
with lower levels of depression were found to do better. Risk aversion has been 
identified as a potential treatment predictor in social phobia and generalised anxiety 
disorder, and to affect help seeking behaviours in these populations (Lorian & Grisham, 
2012). Aversion to risk has not been tested in specific phobias but similar results may 
be expected in this population as avoidance of threat is central to the disorder. Likewise, 
safety seeking behaviours that maintain phobic threat beliefs are targeted in most 
exposure therapies. However, we do not know if people who use more or fewer safety 
behaviours prior to treatment are more or less likely to benefit from the intervention. 
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Understanding predictors of treatment outcome in specific phobias requires 
clarity. This is particularly important in the development of new VR treatments 
scenarios can be modified according to the needs of the client group. Furthermore, there 
may be differences between those who benefit from VR based therapies and those that 
benefit from face to face therapies. Therefore, it is important to consider predictors of 
change when developing new VR interventions, particularly as treatment content moves 
away from simply replicating in vivo therapies.  
Summary 
To date, exposure treatments in virtual reality have largely used habituation to 
feared stimuli to create cognitive change. This is no longer considered the most 
effective approach. Physiological arousal and self-reported ratings of fear and anxiety 
are discordant in specific phobias both in vivo and in virtual reality. However, people 
with a fear of heights appraise these physical sensations as threatening. It is not clear 
who will benefit most from treatment for specific phobias, but this is needed to inform 
future therapies. To enhance cognitive change and maximise outcomes, components of 
virtual reality, augmentations to treatment and predictors of therapeutic change need to 
be investigated.  
Current study 
The aim of the study was to test the effects of increased physical arousal in an 
automated virtual reality treatment for fear of heights. In the current study, aerobic 
exercise was used to manipulate physiological arousal by increasing heart rate. A target 
heart rate was achieved by a short period of vigorous cycling to induce arousal. 
Additional physical effects of exercise included breathlessness, perspiration and 
physical tiredness. Increased feelings of self-efficacy were anticipated in the exercise 
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group that would allow participants to face more challenging stimuli. It was expected 
that increasing arousal would affect subjective fear and there would be a greater 
mismatch between anticipated and actual outcomes of facing feared stimuli. This 
mismatch was anticipated to lead to new learning about the phobic stimulus and to 
promote new learning.  
Primary hypothesis: Increasing physiological arousal in virtual reality will 
significantly reduce degree of conviction in threat beliefs, in comparison to virtual 
reality alone.  
Hypothesis 2: Self-efficacy and subjective units of distress will mediate the effect of 
increased physiological arousal on change in belief conviction.  
Hypothesis 3: Tendency to use safety behaviours, risk aversion, mood, trait anxiety, 
sensitivity to internal phobic cues and self-reported fear of heights are predictors of 
belief reduction in virtual reality.  
 
Method 
Design 
The study used a between-groups, randomised controlled experimental design. 
All participants received a brief automated immersive virtual reality treatment for fear 
of heights and were randomly assigned to the experimental ‘exercise’ condition or the 
control ‘no-exercise’ condition. The experimental manipulation was carried out prior to 
each VR session (see Figure 3 for study procedure). The primary outcome variable was 
a belief rating of what they most feared happening when encountering heights. 
Additional predictor variables were completed by all participants at baseline and there 
were also repeated assessments for mediation analysis.   
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Ethical consideration 
 The study was reviewed and approved by the Royal Holloway Research Ethics 
Committee (REC project ID: 862; see Appendix A). As the study was conducted in the 
Department of Psychiatry at the University of Oxford, ethical approval was also granted 
by the University of Oxford Medical Sciences Interdivisional Research Ethics 
Committee (REF: R58997/RE001; see Appendix B). Participants were required to 
complete questionnaires about anxiety, mood, risk aversion, safety behaviours, and fear 
of heights. The potential for these questionnaires to prompt difficult feelings was 
discussed with all participants in person and they were provided with a debrief 
information sheet that included signposting to external services (see Appendix C). 
Participants were also required to complete a short period of physical exercise. They 
were screened for health conditions prior to taking part and they were provided with 
water during participation. Virtual reality is not suitable for people with significant 
balance problems, some ocular and visual conditions, and people with photosensitive 
epilepsy. Participants were screened for suitability and any physical limitations were 
discussed prior to taking part. In some people, immersive virtual reality can cause 
cybersickness (motion related nausea and dizziness). If needed, participants could leave 
virtual reality at any point by removing the headset.  
Participants and recruitment 
60 participants were recruited via advertisements aired on local radio 
(Oxfordshire, UK) over a 6-week period and posters in the local area (see Appendix D). 
People replied to the advertisement via text and were sent a link to an online screening 
questionnaire to assess eligibility. Participants aged between 18 – 65 years old, scoring 
>45 on the anxiety subscale and >8 on the avoidance subscale of the Acrophobia 
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Questionnaire (AQ) were included in the study. The mean scores of people with a fear 
of heights on the AQ are 48 to 60 on the anxiety subscale and 4 to 14 on the avoidance 
subscale (Cohen, 1977; Baker, Cohen & Sanders, 1973). Cut offs for this study were 
based on previous studies and the range expected to detect fear of heights (Șoflău & 
Matu, 2016). Individuals with photosensitive epilepsy, no stereoscopic vision or balance 
problems were unable to complete a short period of intense exercise on an indoor bike, 
or people who were currently receiving treatment for fear of heights were excluded. See 
Figure 2 for consort diagram. Eligible participants were required to attend a 90-minute 
testing session at a virtual reality laboratory at the University of Oxford.  
Piloting and service user involvement 
Piloting took place prior to recruitment to assess acceptability of the study 
design and efficacy of the manipulation. Four participants took part in piloting. Two of 
the pilot participants did not have a fear of heights and were used to assess the 
procedure and manipulation; how quickly the target heart rate could be reached and how 
long it was maintained following two minutes of exercise. The two participants with a 
fear of heights completed the screening questionnaire and met the eligibility criteria to 
take part. They were asked to give feedback on the study and the suitability of the 
procedure for people with a fear of heights. This included the order of the 
questionnaires, introduction to the lab and explanation of the study, management of 
anxiety during testing and the final debrief.  
Power analysis 
Power analysis was conducted using GPower to determine appropriate sample 
sizes to test the primary hypothesis. Effect sizes were categorised according to Cohen’s 
(1988) categorisation of small (d=0.2), medium (d=0.5), and large (d=0.8) effect sizes.  
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To calculate sample size for a linear mixed effects model that would detect a large 
effect size equivalent to Cohen’s d (d=0.8), statistical power (1 - β) was set at 0.80 and 
the alpha level was set at α = 0.05. The recommended sample size for each group was 
26. The reason for powering the study to detect a large effect was because the aim of the 
manipulation was to test an augmentation that would be clinically relevant and 
noticeable to most patients. 
Randomisation 
Allocation to group was set up by an independent researcher. Envelopes were 
labelled 1-60 and contained the randomisation ‘exercise’ or ‘control’. These were then 
used by the researcher (JM). The envelope was opened for each person when they 
arrived at laboratory for testing. Participants were told they would either be completing 
‘fast cycling’ or ‘slow cycling’ but no further explanation was given until the debrief.  
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Figure 2. Consort diagram 
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Measures 
Participants completed measures at screening, pre-test, during and post-test (see 
Appendix E). Participation took place during a single 90- minute session so pre and 
post-test measures were directly before and after the intervention.   
Screening measures 
The Acrophobia Questionnaire (AQ) is a 20-item self-report questionnaire 
assessing anxiety and avoidance of height-related situations and is divided into two 
subscales (Cohen, 1977). The measure has good validity and test re-test reliability 
(r=0.82) for anxiety and for avoidance (r=0.86), (Baker, Cohen, & Saunders, 1973).  As 
the AQ is a clinical measure of acrophobia, it was only be used to assess eligibility. The 
AQ is scored by totalling the scores with a range of 0-180 for total score, 0-120 for the 
anxiety subscale and 0-60 for the avoidance subscale.  
Participants were also asked about their current exercise habits and were 
screened for health conditions that would prevent participation in virtual reality or 
during the exercise phase. Mental health histories were discussed verbally to ensure 
eligibility. Participants were also asked whether they were currently receiving any 
treatment for their fear of heights. See Appendix E1. 
Primary outcome 
Fear of heights belief and conviction. Participants were asked what they most 
feared happening when they were in high places and asked to rate how certain they were 
that this would happen, on a scale from 0-100%. The belief was established in a brief 
clinical interview and is in line with Craske et al’s. (2014) recommendation for 
measuring expectancy violation. See Appendix E2. 
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Predictor measures  
 Predictor measures were completed at baseline on arrival at the virtual 
reality lab on the day of testing. These included the Safety Behaviour Inventory (SBI), 
The Risk Orientation Scale (ROS), The Attitudes Toward Heights Questionnaire 
(ATHQ), and The Beck Depression Inventory (BDI). Three anxiety measures were also 
included at baseline: The Anxiety Attitude and Belief Scale (AABS-R 33), Anxiety 
Sensitivity Index-3 (ASI-3) and The Beck Anxiety Inventory (BAI). Multiple measures 
of anxiety were used at baseline as they measured different features of anxiety, which 
were expected to be predictive of treatment response. These included attitudes and 
beliefs towards anxiety, sensitivity to physiological sensations of anxiety and self-
reported anxiety over the past week. Perceived self-efficacy and subjective units of 
distress were measured at multiple time points throughout the study. These were as 
follows: after completing the baseline questionnaires on the day of testing (baseline), 
after the first period of cycling prior to the first scenario (time 2), after finishing the first 
scenario in VR and taking the headset off (time 3), after the second period of cycling 
(time 4), and at the end of the second scenario prior to the debrief (time 5).  
Safety Behaviour Inventory (SBI) is a new 20-item scale that assesses the latent 
trait tendency to use safety behaviours. The scale is currently unpublished (Brown, see 
Appendix E3). Acceptable psychometric properties have been demonstrated in previous 
major research projects conducted at Royal Holloway, University of London. The SBI 
was scored using the following subscales: physical vigilance (sum of items 19, 3, 14, 
10, 7, 15, 4), cleanliness (sum of items 8, 6, 1, 12, 11) and checking (sum of items 16, 2, 
5). 
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The Risk Orientation Scale (ROS) is a 15-item scale to assess risk aversion. 
The scale is currently unpublished (Brown, see Appendix E4). Acceptable psychometric 
properties have been demonstrated in previous major research projects conducted at 
Royal Holloway, University of London. The ROS was scored using the following 
subscales: financial risk (sum of items 13, 11, 3, 5, 2), social risk (sum of items 10, 15, 
8, 7, 4) and physical risk (sum of items 1, 6, 12, 14, 9). 
The Attitudes Toward Heights Questionnaire (ATHQ) is a 6-item self-report 
semantic scale that assesses attitudes towards height-related situations (Abselson & 
Curtis, 1989). Total scores range from 0-60, with higher scores indicating greater 
negative attitudes. Items are summed for a total score. See Appendix E5. 
The Anxiety Attitude and Belief Scale (AABS-R 33) is a 33-item self-report 
measure to assess ongoing beliefs and expectancies related to anxiety (Brown, Hawkes, 
Cooper, Jonsdottir & Tata, 2015). Initial construct validity has been established and 
model-based reliability was good at 0.97. Items on the AABS-R-33 are recoded from 0-
100 to 1-7 and summed for a total score. See Appendix E6. 
Anxiety Sensitivity Index-3 (ASI-3) is an 18-item self-report measure assessing 
fear of anxiety related symptoms (Taylor et al., 2007). The measure has adequate 
reliability (α =0.89) for the total measure (Osman et al., 2010) and good validity. Items 
are summed for a total score. See Appendix E7. 
The Beck Depression Inventory (BDI) is a 21-item self-report questionnaire 
that measures symptoms of depression over the past 14 days (Beck, 1967). Ratings are 
made on a scale of four statements ranging in intensity from 0-3. Total scores range 
from 0-63, with higher scores indicating severe depression. The measure has established 
construct validity, high internal consistency ranging from (α =0.72-0.83) and test re-test 
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reliability over one week ranging from (r=0.86-0.81) in clinical and non-clinical 
samples (Beck, Steer & Garbin, 1988). Items are summed for a total score. See 
Appendix E8. 
The Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire that 
that rates anxiety over the past week. Ratings are made on a scale of 0 (not at all) to 3 
(severely). Total scores range from 0-63, with the higher scores indicating severe 
anxiety. The measure has high internal consistency (α=.92) and good test re-test 
reliability over one week of (r=0.75), (Beck, Epstein, Brown, & Steer, 1988). Items are 
summed for a total score. See Appendix E9. 
Perceived self-efficacy was measured by two questions, level of confidence in 
their ability to complete the scenario and to face height related stimuli in vivo. This was 
measured on a scale from 0-100, similar to previous studies (Williams & Watson, 
1985). Participants were asked “how able to cope do you feel, 0 is not at all, 100 is 
totally able to cope” before and after each exercise phase, and at the end of the scenario. 
See Appendix E10. 
Subjective units of distress Participants were asked “how distressed do you feel, 
0 is not at all, 100 is very distressed”. Ratings were taken at baseline, before and after 
each exercise phase, and at the end of the scenario. See Appendix E10. 
Physiological measures 
Heart rate was recorded in beats per minute (bpm) from baseline to completion. 
A resting baseline heart rate in bpm was recorded whilst they completed the initial 
questionnaires. In the experimental condition, heart rate was elevated to approximately 
80% of their maximal, calculated by age using the 220-age equation outlined by Fox et 
al. (1971). Without using specialist equipment to calculate maximal heart rate, it is 
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difficult to validate or establish reliability with the 220-age equation, or similar 
(Sarzynsky et al., 2013). However, it is a widely used equation and it’s use in this study 
was to ensure the manipulation was effective at inducing physiological arousal in the 
experimental group. To check the manipulation was effective, an average of each 
participant’s heart rate during the virtual reality scenario was compared by group. 
Participants wore the heart rate monitor from arrival until the end of testing so any 
variation in timings did not impact on the collection of heart rate data. 
Equipment 
Virtual reality technology  
The virtual reality technology used for the study was the same as that outlined in 
the main trial of the automated fear of heights treatment (Freeman et al., 2018). The 
following description is quoted from the trial paper: “The application is a CE-marked 
class I active medical device (device code Z301 [standalone software]), in conformity 
with the essential requirements and provisions of EC directive 93/42/EEC (medical 
devices). The software was developed using Unity3D (version 5.6.0f3 [64-bit]; Unity 
Technologies, San Francisco, CA, USA) and delivered using a gaming personal 
computer (Chillblast Fusion Strix Gaming PC, Intel Core i7-7700K processor, 16 GB 
DDR4 3000 MHz memory, ASUS GeForce GTX 1080 8GB graphics card, 500 GB M.2 
solid state drive/3 TB hard disc drive; Chillblast, Poole, UK) and the HTC Vive (HTC 
Corporation, New Taipei City, Taiwan)—a consumer VR head-mounted display that has 
associated hand controllers and headset tracking”  
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Indoor static bike 
The static bike used in the study was a JLL IC260 Indoor cycling 2018 with a 
15kg flywheel and adjustable resistance. It was positioned next to the allocated virtual 
reality space to minimise the time spent moving between areas.     
Heart rate monitor 
 A Polar H10 heart rate monitor was used to record beats per minute. Polar heart 
monitors have been validated to accurately measure heart rate variability in children 
(Gamelin, Baquet, Berthoin & Bosquet, 2008) and adults (Hernando, Garatachea, 
Almeida, Casajús & Balión, 2018).  
Features of the virtual environment 
Participants were standing throughout the scenario, so their body position 
matched that of their avatar. Tracking was established at the beginning so that 
participant movement was mirrored by the avatar. The scenario was not designed to be 
openly explored but participants could move freely, crouch, turn, look around and pick 
up items in close proximity. This allowed the scenario to be run in a small room. Voice 
recognition was used in the original trial of the fear of heights treatment but for the 
purposes of this study, a virtual watch worn by the participant’s avatar was used to 
interact with the therapist (see Appendix F1). This was a feature in the original study 
and was chosen as the main method of feedback in the scenario due to difficulties with 
the voice recognition software during piloting. The watch created a screen of buttons 
that were used to answer pre-scripted questions. 
Treatment 
 The automated virtual reality treatment was designed by Oxford VR and was 
trialled in six 30-minute sessions to test efficacy with good effect (d=2.0) (for more 
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detail see Freeman et al., 2018). The treatments can be used as a self-contained 
intervention as it has an in-built virtual therapist, and also with an external therapist in 
clinical settings. The treatment is a cognitive therapy rather than an exposure therapy as 
users do not wait for their anxiety to reduce when facing feared stimuli. Instead, it uses 
a series of behavioural experiments that allow users to drop safety seeking behaviours, 
test out their predictions and challenge phobic threat beliefs.    
Virtual reality scenario 
Therapist’s office: All participants started the therapist’s office. They were 
asked questions about their fear of heights including which of the following common 
fears reflected their own worries: ‘I will trip and fall’, ‘the structure will collapse’, ‘I 
will try to jump’ or ‘I’m not sure’. Participants then rated how certain they were that 
this would happen if they were exposed to heights.  
The atrium: Participants were taken to the atrium (see Appendix F2) and asked 
to choose a floor between 1 and 5 that where they would feel moderately anxious. The 
coach then took them in a lift to the chosen floor and started the next scenario.  
Scenario 1: Participants were positioned behind a waist height barrier when they 
started each floor. On floors one and two, this was a solid colour and on floors three 
upwards, the barrier was transparent to imitate glass. Regardless of the floor chosen, all 
participants completed the same tasks in the first scenario. Following an introduction to 
the floor and initial psychoeducation, the therapist asked participants if they would like 
to lower the barrier. This was lowered in three stages and participants were prompted to 
look around their environment and try things like swaying from side to side. Once the 
barrier had been lowered all the way, a bucket with coloured balls appeared next to the 
participant (see Appendix F3). The therapist asked them to crouch down, pick up the 
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balls and throw them over the edge of the balcony. Participants were asked to watch the 
balls landing in the atrium, try and stand near the edge and to stand on one leg. Once all 
tasks had been completed participants could choose to progress to the next floor. If they 
did not feel any safer in comparison to when they started, they could choose to repeat 
the same floor.  
Scenario 2: If participants started between floors one and four, the second 
environment was similar. However, if they started on floor five and progressed to six, 
the balcony had the appearance of a building site and the barrier was cracked. 
Regardless of the appearance of the floor, the barrier lowering task was repeated. The 
next tasks consisted of a xylophone that was played over the edge of the balcony or a 
painting that was completed in the same position. Whichever floor participants were on 
at the time, the second scenario always involved the platform task. This was a metal 
looking platform that participants controlled with a lever (see Appendix F4). The 
platform was extended into the atrium from the balcony and brought back again to 
complete the task. 
End: At the end of the scenario, participants were taken down to the atrium.  
Psychoeducation 
Psychoeducation about fear of heights was delivered by the virtual therapist 
throughout the scenario. She stood next to the participants’ avatars and talked through 
each task. The psychoeducation was grounded in cognitive behavioural therapy. The 
therapist explained why we used safety behaviours and gave examples such as, “closing 
your eyes when you are up high or not looking down”. Avoidance was also 
discouraged, for example, “see what happens when you stay where you are”. The 
therapist also prompted participants to adopt more confident and relaxed body postures, 
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using phrases such as, “try to imagine you are someone who isn’t afraid of heights, like 
Superman or Wonder Woman”. When a new task was presented, the therapist prompted 
participants to appraise negative thoughts and mental images differently than before, for 
example, “all sorts of things must be going through your head right now, but it is 
important to remember that they are just thoughts”. The psychoeducation component 
was the same for all participants with small variations depending on the task being 
completed and whether they felt safer than before.  
Procedure  
Eligible participants were contacted by telephone. The study was described and 
the requirements for participation were outlined. Exclusion criteria were also discussed 
and, if eligible, they were invited to attend for testing. The participant information sheet 
(see Appendix G) and directions were sent via email. Participation took place in a single 
visit to the virtual reality laboratory in the University of Oxford’s Department of 
Psychiatry at the Warneford Hospital, Oxford. The study was verbally described for a 
second time at arrival, to ensure they understood the requirements and were able to 
provide informed consent. They were also offered another copy of the participant 
information sheet to read. Two consent forms were read and signed before starting, one 
kept by the researcher, one by the participant (see Appendix H).  
Participants were fitted with a Polar H10 heart rate monitor before completing 
the baseline questionnaires. This provided a resting heart rate as the questionnaires took 
approximately 20 minutes to complete. Next, a verbal discussion about their fear of 
heights identified the primary fear belief (What do you most fear happening when you 
encounter heights?) and their conviction rating (0% – I’m certain it won’t happen, 100% 
- I’m certain it will happen). They were also asked to rate how distressed they felt (0 – 
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Not at all, 100 – Very distressed) and how able to cope their felt (0 – Not at all, 100 – 
Totally able to cope). These ratings were rated verbally at multiple timepoints 
throughout testing.  
Participants entered virtual reality and remained in the scenario until reaching 
their chosen floor. The scenario was paused to allow them to come out of virtual reality 
and complete the first stage of the exercise manipulation. Pausing the scenario 
prevented progression through the tasks but movement in the virtual environment was 
unaffected.    
Next, participants in the experimental condition completed 1 minute of cycling 
to raise their heart rate to the target bpm (80% of their maximal heart rate) and take up 
to 15 seconds to rest once this had been reached. Participants cycled again until it 
reached the target bpm and maintained this for 2 minutes. This technique was used as 
piloting found it to be the most effective way of maintaining an increased heart rate. As 
heart rate was recorded for all participants, it ensured there was a difference in arousal 
between the groups and that the manipulation was effective. In the control condition, 
participants were asked to monitor their heart rate in the same way as the experimental 
condition, but they cycled for 3 minutes ensuring that it did not go above resting. This 
meant using the lightest setting and cycling very slowly.  
Once complete, participants were asked to verbally rate how distressed and how 
able to cope they felt. They were returned to VR within 30-60 seconds and the scenario 
was resumed. Once all the tasks for the current floor had been completed, the participant 
was given the option to repeat the same floor or continue to the next, depending on 
whether they felt safer and ready to progress. They were taken out of virtual reality 
again and asked to verbally rate their distress and ability to cope. Participants repeated 
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the 3 minutes of cycling according to their allocation and returned to VR for the final 
scenario.  
At the end of the second scenario participants were asked to re-rate the fear 
belief that was identified at the start. They were given a debrief information sheet and 
signposted to NHS services if they wanted to pursue additional treatment for their fear 
of heights. Figure 2 outlines the testing procedure. 
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Figure 3. Study procedure 
Enter VR 
Scenario resumed; tasks completed for 
this floor.  
Enter VR 
Scenario resumed; tasks completed for 
this floor.  
Exit VR 
Rate SUDS & self-efficacy 
Rate conviction in fear belief 
 
Debrief 
Exit VR 
Rate SUDS & self-efficacy 
Rate conviction in fear belief 
Debrief 
Exit VR 
Cycle to target bpm, rest for up to 15 
seconds (approx. 1 minute in total). 
Cycle at target bpm for 2 minutes. 
Rate SUDS & self-efficacy 
 
Exit VR 
Cycle for 3 minutes without raising 
heart rate above resting rate. 
Rate SUDS & self-efficacy 
 
Exit VR 
Cycle to target bpm, rest for up to 15 
seconds (approx. 1 minute in total). 
Cycle at target bpm for 2 minutes. 
Rate SUDS & self-efficacy 
 
Exit VR 
Cycle for 3 minutes without raising 
heart rate above resting rate. 
Rate SUDS & self-efficacy 
 
Enter VR 
Scenario resumed; tasks completed for 
this floor.  
Enter VR 
Scenario resumed; tasks completed for 
this floor.  
 Heart rate monitor fitted. Baseline measures completed; SUDS & self-efficacy rated. 
Fear of heights discussed, primary fear belief identified and rated.  
Enter VR for calibration and introduction to the scenario. Meet virtual therapist, 
starting floor (1-5). Enter lift, doors open, scenario paused.  
Experimental condition              Control condition 
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Analytic plan  
Primary analysis 
The primary hypothesis that increased physiological arousal reduces conviction 
in beliefs about heights relative to control was tested using a linear mixed effects model, 
accounting for baseline conviction and fear of heights (AQ) scores from screening. This 
approach was used as it accounts for repeated measures of conviction and is suitable for 
mediation analysis (hypothesis two). Residuals were visually checked for normality 
using histograms to assess distribution and Q-Q plots to assess homoscedasticity. Linear 
mixed effects models are robust to deviations from normality and missing data, so the 
latter was accounted for within the model. A random intercept was included to account 
for the repeated measures of conviction in each participant. Analysis was completed 
using RStudio version 1.2.1335 statistical package and SPSS statistics® (Version 25). 
The first model tested the manipulation to see whether increased physiological 
arousal (as measured by heart rate) was maintained throughout the virtual reality 
scenario. The second model tested the effect of condition on conviction in belief about 
heights. Significance was set to a value of p=<0.05. Cohen’s d effect sizes were 
calculated by dividing the mean difference by the pooled standard deviation at baseline. 
Effect sizes were categorised as small (0.2), medium (0.5) and large (0.8) according to 
Cohen (1988).     
Secondary analysis 
Linear mixed effects models were used to test hypothesis two; self-efficacy and 
subjective units of distress mediate the effect between increased physiological arousal 
and belief conviction. This approach is outlined by Whittle, Mansell, Jellema & van der 
Windt (2017) and overcomes some of the issues such as unmeasured confounders in the 
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Baron and Kenny method (1986). If no effect was found between physiological arousal 
and change in belief conviction (primary hypothesis), the effect of condition on each 
potential mediator would be tested individually to test whether the manipulation had 
changed them.   
Hypothesis three was tested using individual linear regressions. The aim was to 
test the individual effect of the predictor variables on conviction in beliefs about heights 
post intervention. Individual regressions were completed both with and without 
accounting for baseline conviction.  
 
Results 
Table 5 shows the baseline characterises of the participants and means of total 
and subscale scores on the Acrophobia Questionnaire (AQ) used to assess fear of 
heights at screening. There were slightly more females than men. The mean age was 41 
years old, and the participants in the control group were slightly older than in the 
exercise group. The exercise group reported a slightly greater fear of heights than the 
control group at screening. There were only 3 individual items of missing data on the 
BAI. These items were prorated prior to analysis. There was no missing data on the 
primary outcome. Participants completed two floors in virtual reality that each took 
approximately 15 minutes to complete. This varied as some people completed the tasks 
quicker than others, but approximate time spent in VR was 30 minutes as estimated 
from piloting the procedure.   
The most common threat belief reported was losing balance and falling (n=23). 
Fears about the internal experience of anxiety was the next most reported threat belief 
(n=11) with participants associating increased arousal with falling (e.g. “I’ll feel 
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nauseous and dizzy and fall over the edge”). The remaining threat beliefs reported were 
something unknown that was out of their control making them fall (n=9), the structure 
collapsing (n=7), jumping over the edge (n=7) and falling without an explanation as to 
how this would happen (n=3).  
 
Table 5. Participant demographics and screening scores 
 Exercise (n=30) Control (n=30) 
Age 
years, range, (SD) 
38.67 (M), 24-52 (range),  
9.58 (SD) 
43.57 (M), 27-58 (range), 
8.85 (SD) 
 
Gender 
female (F), male (M) 
 
15 F/15 M 
 
17F/13M 
 
AQ total  
Mean, (SD) 
 
83.50 (16.97) 
 
76.63 (13.85) 
 
AQ anxiety  
Mean, (SD) 
 
68.1 (12.67) 
 
60.53 (10.32) 
 
AQ avoidance 
Mean, (SD) 
 
15.93 (4.65) 
 
13.87 (4.03) 
 
Hypothesis 1: Effect of increased physiological arousal on fear of heights belief 
conviction. 
Table 6 shows the mean scores for pre and post-conviction and heart rate, split 
by group. Model 1 tested the manipulation. The cycling manipulation successfully 
raised physiological arousal (as measured by heart rate) in the exercise group 
throughout the virtual reality intervention. The heart rate of the exercise group was 
faster by an average of 36 beats per minute and was significantly different from the 
control group (p<0.0001). Model 2 tested the between groups effect in threat belief 
conviction ratings, accounting for baseline conviction and fear of heights screening 
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score. This showed there was no difference between the groups despite the 
manipulation. The mean scores show that conviction reduced in both groups, so post-
hoc exploratory analysis was conducted to assess statistical significance. Assumptions 
of normality were not met so a non-parametric Wilcoxon Signed Ranks Test was used 
to compare pre and post-conviction scores for all participants, which found the virtual 
reality intervention significantly reduced fear of heights belief conviction (Z= -6.08, 
p<0.0001) with a large effect size (d=1.0). 
 
Table 6. Linear mixed effects models testing manipulation efficacy and between group 
differences on belief conviction, accounting for baseline AQ score 
 Exercise 
group: 
mean (SD)  
Control 
group: 
mean (SD)  
Adjusted 
mean 
difference 
(95% CI)  
p-value  Effect size 
(Cohen’s d) 
Model 1: 
(manipulation 
check) 
 
Heart rate 
(bpm) 
Pre 
 
Post 
 
 
 
 
 
 
 
77.47 
(12.09) 
113.3 
(13.54) 
 
 
 
 
 
 
77.37 
(11.17) 
77.37 
(13.54) 
 
 
 
 
 
 
35.60 (35.14; 
39.05) 
 
 
 
 
 
 
<0.0001 
 
 
 
 
 
 
2.9 
Model 2:  
 
Belief 
conviction 
Pre 
 
Post 
 
 
 
 
 
69.42 
(22.79) 
45.50 
(23.09) 
 
 
 
 
70.33 
(21.77) 
48.83 
(22.43) 
 
 
 
 
-3.08 (-12.89;    
 6.74) 
 
 
 
 
0.56 
 
 
 
 
0.1 
Notes: Measures included in each linear mixed effects model were as follows: model 1 = heart 
rate and condition; model 2 = belief conviction, baseline AQ and condition. 
Abbreviations: SD, standard deviation; CI, confidence intervals; AQ, acrophobia 
questionnaire; bpm, beats per minute. 
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Hypothesis 2: Mediation analysis 
 There is no main manipulation effect from the study and therefore no 
manipulation effect for a mediation analysis to explain. However, it is of interest to 
know whether the manipulation did change the hypothesised mediators. Table 7 shows 
the mean scores for the effect of physiological arousal on self-efficacy and subjective 
units of distress. There was no effect of condition on either of these measures. However, 
the mean scores show that self-efficacy increased over time for both groups so post-hoc 
exploratory analysis was completed to test change in self-efficacy across the whole 
sample. Assumptions of normality were not met so a non-parametric Wilcoxon Signed 
Ranks Test was used to compare self-efficacy scores at baseline and T5, which 
indicated that self-efficacy significantly improved over time for all participants (Z= -
4.04, p<0.0001) with a large effect size of (d=0.8). Similar analysis was conducted to 
assess change in scores from baseline to T5 on distress as assumptions of normality 
were also not met. There was no significant change in distress over time across the 
whole sample (Z= -0.03, p=0.98), which supports existing research that within group 
fear reduction does not predict outcomes (Baker et al., 2010).    
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Table 7. Linear mixed effects models testing the effect of physiological arousal on self-efficacy and subjective units of distress, 
accounting for baseline scores 
 Exercise group: 
mean (SD)  
Control group: 
mean (SD)  
Adjusted mean difference 
(95% CI)  
p-value  Effect size 
(Cohen’s d) 
Model 3: (self-
efficacy) 
 
Baseline 
Time 2 
Time 3 
Time 4 
Time 5 
 
 
 
54.17 (28.71) 
73.42 (28.39) 
74.00 (23.76) 
81.50 (23.82) 
82.50 (26.77) 
 
 
 
61.17 (21.68) 
74.33 (26.06) 
73.67 (28.83) 
77.83 (23.12) 
76.00 (27.02) 
 
 
 
 
-0.04 (-13.30; 13.21) 
 1.21 (-12.05; 14.46) 
 4.54 (-8.71; 17.80) 
 7.38 (-8.71; 17.80) 
 
 
 
 
0.99 
0.86 
0.50 
0.28 
 
 
 
 
0.03 
0.01 
0.16 
0.24 
Model 2: (suds)  
 
Baseline 
Time 2 
Time 3 
Time 4 
Time 5 
 
 
16.67 (20.31) 
14.83 (20.15) 
26.00 (26.27) 
15.23 (22.39) 
19.00 (25.20) 
 
 
20.77 (18.35) 
11.97 (16.13) 
34.83 (25.58) 
23.17 (23.36) 
23.07 (25.59) 
 
 
  
 4.24 (-7.17; 15.66) 
-7.46 (-18.87; 3.96) 
-6.56 (-17.97; 4.86) 
-2.69 (-14.12; 8.73) 
 
 
 
 0.47 
0.20 
 0.26 
 0.64 
 
 
 
0.16 
0.34 
0.35 
0.16 
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Hypothesis 3: predictors of belief change 
Total scores on the BAI and ASI were within normal ranges indicating both 
groups were in the ‘low anxiety’ range. Likewise, scores in the BDI indicated ‘minimal’ 
depressive symptoms. See Appendix I for mean scores on the predictor measures. 
Table 8 shows the results from linear regressions on individual predictor 
variables. The social risk subscale of the risk orientation scale was significantly 
associated with conviction (p=0.05) but after accounting for baseline conviction it was 
no longer significant. The cognitive subscale of the ATHQ and the BDI were both 
approaching significance (p=0.07) but this was also not maintained when accounting for 
baseline conviction. None of the predictor variables significantly predicted conviction 
change.  
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Table 8. Individual linear regressions to test incremental prediction of the baseline predictors on post-conviction, controlling for pre-
conviction 
  
 
 
Controlling for baseline conviction 
 
  
F-statistic 
 
Ad R
2
 
 
p-value 
 
F-statistic 
 
Ad R
2
 
 
p-value 
 
ATHQ (cognitive subscale) 
 
3.35 
 
0.04 
 
0.07 
 
0.34 
 
0.34 
 
0.52 
ATHQ (danger subscale) <0.01 -0.02 0.95 16.09 0.34 0.97 
BAI 2.91 0.03 0.11 17.43 0.36 0.87 
SBI (physical vigilance) 0.05 -0.02 0.82 16.29 0.34 0.59 
SBI (cleanliness) 1.49 0.01 0.23 16.07 0.34 0.86 
SBI (checking) 0.57 -0.01 0.45 16.18 0.34 0.68 
ASI-3 (physical sensitivity) 3.20 0.04 0.08 17.61 0.36 0.16 
ASI-3 (cognitive sensitivity) 0.33 -0.01 0.57 16.06 0.34 0.94 
ASI-3 (social sensitivity) 1.82 0.01 0.18 16.07 0.34 0.87 
AABS2-R-33 0.71 -0.01 0.41 16.18 0.34 0.69 
ROS (financial risk) 0.17 -0.01 0.68 16.29 0.34 0.58 
ROS (social risk) 4.08 0.05 0.05 17.79 0.36 0.14 
ROS (physical risk) 2.16 0.02 0.15 16.41 0.34 0.50 
BDI 3.36 0.04 0.07 16.59 0.35 0.41 
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Discussion 
This study tested whether increasing heart rate increased cognitive change in a 
fear of heights treatment, in order to test the broader theoretical view that deepening 
extinction is clinically valuable. The aim was to investigate whether combining 
physiological arousal with phobic cues in virtual reality increases new learning about 
feared stimuli and reduces belief conviction. Potential predictors of conviction change 
were also tested.  
It is important to highlight that the manipulation worked: heart rate was 
significantly elevated and sustained in the vigorous exercise group (while it did not 
change in the control group). Therefore, the study was able to test the main hypothesis. 
The results of the analysis testing the primary hypothesis showed that increasing 
physiological arousal did not have an effect on the change in threat belief conviction. 
There was not even an indication of a group difference. There was, however, a large 
reduction in belief conviction for all participants, regardless of group allocation, after 
completing the intervention. As improvement was seen regardless of condition, the 
main conclusion is that elevating physiological arousal is not required in virtual reality 
treatments for fear of heights to achieve cognitive change. It is possible that all 
participants experienced anticipatory anxiety before their session, elevating 
physiological arousal prior to arrival. However, excessive levels of arousal are clearly 
not required to achieve positive effects. Alternatively, it may be that conviction change 
in both groups was achieved via different routes and that deepening extinction (i.e. the 
manipulation group) was more robust to fear renewal. As follow up data were not 
collected, the study was not capable of testing whether fear was more or less likely to 
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return. Future research should include real world behavioural avoidance tests and 
multiple follow up time points to test the longevity of positive treatment outcomes.  
 Cognitive change is achieved in habituation models by exposing the phobic 
person to feared stimuli to demonstrate that what they fear will happen, does not 
happen. This challenges their beliefs about the stimuli and therefore violates expectancy 
(anticipated versus actual outcome). However, as physiological arousal and distress did 
not predict the decrease in belief conviction, it can be assumed that conviction change 
occurred as a result of other treatment components. These may include the removal of 
safety signals, varying intensity of the stimuli, or violating expectancy by completing 
tasks that are unachievable in the real world. All of these treatment components sought 
to create new learning by testing out dysfunctional beliefs in a series of behavioural 
experiments. Habituation was not required for cognitive change as self-reported distress 
did not decrease, but self-efficacy did improve across the whole sample, suggesting 
participants felt more able to cope with heights regardless of their level of arousal and 
fear. This interpretation of the data should be considered cautiously as these treatment 
components were not tested individually and mediation analysis was not completed. 
Further research is therefore recommended to make conclusions about the role of each 
component on cognitive change. 
Deepening extinction was hypothesised to enhance exposure as suggested by 
Craske and colleagues (2014) but this was not supported in the current study. One 
reason for this finding is that physiological arousal is not appraised as threatening by all 
participants. Participants in this study reported a range of phobic beliefs including, fear 
of losing balance, the structure collapsing, something outside of their control causing 
them to fall and fear of feeling anxious. Participants who feared the latter, found the 
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feeling of anxiety aversive and believed it would increase their risk of falling. 
Therefore, it is possible that raising physiological arousal is an effective augmentation 
but only in subgroups of people who associate falling with anxious arousal. This study 
was not powered to detect these effects but future research into treatment differences 
based on subtypes of phobic belief is warranted.   
As discussed in the systematic review, most virtual reality treatments for 
phobias use hierarchical exposure models and seek to create environments that mirror 
the real world and maximise fear responses. The results from this study suggest 
treatment components targeting cognitive change should be prioritised in the 
development of new therapeutic content. Findings from Freeman et al (2018) trial of the 
automated virtual reality treatment used in this study is supported by the within group 
conviction change for all participants. Large effect sizes were found in both studies 
(although larger in the original trial) despite pausing the scenario on three occasions to 
complete the manipulation in the current study. The treatment is therefore robust to 
breaks in presence as belief conviction significantly reduced after completing only two 
levels in virtual reality (approximately 30 minutes). One interpretation is that coming 
out of the scenario was beneficial as it allows participants to push themselves on tasks 
they find challenging, but this was not compared to a scenario where they completed it 
without a break, so is a tentative conclusion. Alternatively, it is possible that stopping 
the scenario increased the use of cognitive safety behaviours that participants may have 
used to complete the scenario.   
The mediation analysis was not completed as the manipulation had no effect on 
conviction. Interestingly, the manipulation also had no effect on either self-efficacy or 
distress. Post-hoc exploratory analysis on self-efficacy found an increase in both groups, 
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suggesting participants felt more able to cope with heights as they progressed through 
the intervention. In comparison, self-reported distress levels did not change significantly 
over time. It is possible that participants felt more able to manage their distress as the 
tasks were designed as a series of behavioural experiments. This meant they were 
encouraged to challenge beliefs about their safety rather than waiting for fear responses 
to reduce. As a result, participants progressed through the scenario regardless of how 
fearful they were feeling. This included completing tasks that are not possible in the real 
world such as the platform task. These were designed to challenge threat beliefs and 
may have increased feelings of self-efficacy more than tasks that could easily be 
achieved in vivo. To understand the added benefit of each type of task delivered in 
virtual reality scenarios, further research is needed comparing different treatment 
components and types of task.   
The non-significant results from the predictor measures for change in the threat 
beliefs were unexpected, particularly for state anxiety, anxiety sensitivity, use of safety 
behaviours, and fear of heights. One explanation is that both groups scored within the 
low anxiety and minimal depression range. Whether similar results would be found in 
phobics with high anxiety or low mood is unknown. It is also possible that an 
association would have been seen at follow-up if data had been collected. High anxiety, 
low mood and reliance on safety behaviours may have made participants less likely to 
re-expose themselves to feared stimuli post intervention, limiting opportunities for 
learning consolidation. It is also important to note that participation in the study 
required a certain amount of motivation, including travelling over an hour to the 
laboratory for a number of participants. Therefore, the sample may have been biased 
towards participants with lower anxiety, stable mood, and higher levels of motivation.  
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The non-significant result between safety behaviour use and conviction change 
may also be explained by low anxiety across the sample. Safety behaviours are an 
importance maintenance factor in anxiety disorders so these results may be different in a 
highly anxious population (Thwaits & Freeston, 2005). Safety behaviours were directly 
targeted in the intervention to achieve cognitive change and they are a common feature 
in fear of heights. Therefore, it is likely that participants in this study used them in the 
context of their phobia but did not use them excessively in other areas of their life. As 
the scores on this measure were analysed as a predictor of change, it is likely that only 
the safety behaviours targeted by the intervention, for example, standing away from the 
edge or looking away, would be significantly associated with conviction change. 
Notably, both the AQ and ATHQ fear of heights measures were not significantly 
related to conviction when accounting for baseline. This is a surprising finding that 
indicates these measures do not capture beliefs about heights and are less sensitive to 
cognitive change, particularly as there was a strong correlation between pre and post-
conviction scores. It also raises questions about how adequate these measures are at 
capturing cognitive change in other studies and whether this changes the interpretation 
of results of previous trials using the AQ and ATHQ as primary outcomes. However, as 
these measures were only completed at baseline, it is possible they would have captured 
change in addition to belief conviction. Given that these measures evidently differ, 
future researchers should carefully consider if they capture the targeted mechanism of 
change and whether beliefs about heights should be measured separately.  
Strengths 
 One of the main strengths of the study was the randomized design. Recruitment 
targets were met, groups were equal, and the randomization was successful. In addition, 
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participants were recruited from the general public, so the sample was more likely to be 
representative of the relevant population. Another particular strength of the study was 
the use of an automated virtual reality treatment as this reduced variation between 
sessions, minimised confounds, and meant participants received similar interventions. 
Whilst the procedure had multiple components, this was achieved seamlessly in the 
virtual reality laboratory as the scenario could be paused and minimal time was required 
to move between the bike and the headset. Another strength is that the manipulation 
clearly worked as intended: heart rate increased in the vigorous exercise group and 
continued to be elevated during the virtual reality intervention. This meant the main 
study hypothesis could be tested and the null result is not due to a failure of 
experimental procedure. 
Limitations 
There were a number of limitations in the study. Firstly, there were no follow up 
data or behavioural avoidance tests used in this study. The target mechanism in 
exposure was violating expectancy so beliefs about heights were rated pre and post-
treatment but it is possible that changes between groups would have been evident over 
time or in a real-life simulation. Given that large treatment effect sizes are often found 
post treatment, it is perhaps more important to collect follow up data in future research 
as fear renewal is common. It would also have been interesting to see whether there 
were any differences between groups during behavioural avoidance tests as heart rate 
variability is more evident in vivo than in virtual reality. It is possible that this could 
have increased tolerance to physical sensations of anxiety and improved performance in 
a behavioural test.    
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Another limitation of the study was that in order to manipulate physiological 
arousal via cycling, participants had to leave virtual reality for 3-5 minutes. Ideally, this 
could have been achieved in the virtual world but to do so would have required 
redesigning the scenario so that the avatar and environment matched the participants’ 
movements. To overcome this issue, participants left virtual reality twice to use the 
bike. Leaving the environment will have broken presence and reminded participants that 
they are safe and cannot fall as anticipated. It also allows them to move their attention to 
the cycling task and take a break from the virtual phobic cues. The timing of the cycling 
differed from previous studies as they were immediately returned to virtual reality after 
cycling but as explained, it does not control for the use of cognitive safety behaviours or 
distraction.  
 When measures were completed presented another limitation, particularly 
subjective units of distress that were measured as the participant left virtual reality. 
Although these weren’t used for the analysis as mediation could not be completed, the 
timing of these measures requires discussion. The decision to rate distress when they 
were not in virtual reality was to minimise disruption to immersion, yet this was already 
occurring by entering and exiting to complete the manipulation. This could have been 
rectified by adding a series of questions to the scenario, but it suffers from similar 
limitations as the cycling. 
 Whilst the manipulation was effective, there were no self-report measures to rate 
subjective experiences of physiological arousal. It was anticipated that raising heart rate 
increased arousal similar to anxiety, but this may have been different for each 
participant. It is also possible that arousal is important, but this may differ according to 
how it is achieved. For example, inducing arousal using imagery related or unrelated to 
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the phobic stimulus may have different effects from cycling. A self-report measure of 
arousal may have identified differences between participants on the content of their 
beliefs and in how they appraise bodily sensations. 
Finally, participants were recruited after responding to a radio advert in 
Oxfordshire, which may not be representative of the wider population of people with a 
fear of heights. Participation also required a high level of motivation due to the location 
of the testing site and the time taken to complete the study. Furthermore, neither 
participant nor researcher were blind to allocation. All these factors combined could 
have biased results and should be considered when interpreting the findings.  
Conclusion 
 This study aimed to investigate whether increasing physiological arousal in a 
virtual reality treatment for fear of heights reduced threat belief conviction. 
Physiological arousal was successfully increased but it did not have an effect on 
conviction change. Deepening extinction by combining interoceptive cues of anxiety 
with external phobic cues did not enhance exposure as hypothesised but this may be 
explained by participant differences in phobic beliefs and threat appraisals of 
physiological arousal. Different methods of increasing arousal may be more beneficial 
than exercise in people with a fear of heights or with lower levels of anxiety sensitivity.  
The results do not support habituation models of exposure as self-reported distress 
remained high despite changes in belief conviction. This supports previous evidence 
that within session fear reduction does not predict outcomes (Baker et al., 2010) which 
contradicts Foa and Kozak’s (1986) emotional processing model of exposure. Feelings 
of self-efficacy were not affected by the manipulation but there was a significant change 
in both groups from pre to post intervention. The results from this study inform the 
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development of future virtual reality treatments, specifically the therapeutic content. 
Increased physiological arousal, at least by the means generated in the current study, is 
not required for treatments to be effective, so researchers should be encouraged to 
develop components targeting new learning and cognitive change rather than increased 
fear responses. It is also recommended that treatment components are tested 
independently to maximise treatment efficacy.    
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Integration 
The aim of this thesis was to bring together, and contribute to, the literature on 
virtual reality as a treatment for specific phobias. The systematic review and empirical 
paper focused on the content of virtual reality treatments to increase understanding of 
current use, treatment mechanisms, and future directions. Virtual reality technology has 
developed substantially in the last decade and we are now on the cusp of clinical 
dissemination, yet relatively little is known about how it differs from traditional 
treatments and therefore, how it can be maximised.  
Challenges of the systematic review 
The systematic review highlighted that most virtual reality treatments for 
phobias are designed to replicate in vivo approaches. There is also substantial variation 
in the use of external components and the overall reporting of therapeutic tools. These 
findings suggested that further examination of treatment mechanisms in virtual reality 
needs to be explored and that more studies should compare treatments instead of non-
virtual controls. It also found that most studies restricted their scenarios to what could 
be achieved in the real-world and that environments that pushed these boundaries have 
yet to be explored.  
Variation in how virtual reality is developed, reported and applied presented 
another challenge for the review. Initially, the plan was to look at the content of all 
anxiety disorders but there were too many papers and therapeutic approaches to make 
sense of current treatment content. A large proportion of these papers were on post-
traumatic stress disorder (PTSD) and many were case reports from military contexts. 
This presented a dilemma as although PTSD was not the topic of empirical project, the 
technology is already integrated into military units so the real-world application could 
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have been examined in depth. Whether to include the literature from other anxiety 
disorders, particularly case reports, was also debated as the cost of developing new 
virtual environments is prohibitive and excluding smaller projects may have limited the 
overall findings. As the empirical study was conducted within a clinical research team, I 
utilised the expertise of other researchers to discuss the topic and narrow down the 
review. As a thorough review of virtual reality treatment content is needed in other 
areas, it was agreed that this larger topic would be completed jointly with other clinical 
researchers, following completion of the doctorate. This allowed me to focus on a 
narrower subject area for this systematic review that would fit into a larger body of 
work post qualification.  
Integration with the empirical project 
The review set up the empirical paper and placed it within the evidence base. 
This was planned from the initial discussions with my research supervisors about future 
directions for virtual reality and current theories of exposure. Integration of the two 
papers developed as the review topic was narrowed down following exploratory 
searches on the initial larger topic, as discussed. Whilst a smaller review of the literature 
was completed prior to the major research proposal, the systematic review was 
completed in conjunction with the empirical paper. The initial review provided a 
background on the development of virtual reality treatments for phobias, gaps in the 
literature and recommendations for future interventions. However, whilst initially 
reviewing the literature identified the value of both papers, it would have been 
beneficial to complete the systematic review prior to developing a research design and 
submitting the proposal.  
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A number of different areas for future research were raised by the systematic 
review that had not been accounted for in the design of the empirical paper. One 
important finding was the lack of follow up data and standardized behavioural 
avoidance tests to measure post treatment fear renewal. Including these measures would 
have substantially increased testing time and may have affected recruitment rates, but if 
planned effectively it could have been achieved. The re-use of existing virtual reality 
scenarios in multiple studies was also raised as an issue in the literature. The automated 
treatment used for the empirical paper had previously been tested and was included in 
the review (Freeman et al., 2018). This allowed me to test a manipulation within an 
evidence-based treatment, but directly highlighted an issue raised in the review; 
economic and time constraints limit the development of new environments for 
experimental investigations. It is unlikely that this could have been changed given the 
time and financial limitations of the project as designing even a simple environment 
would have required a computer scientist capable of building virtual scenarios. 
However, it is possible that small augmentations to the scenario could have been 
achieved in a shorter time frame. This would have allowed existing components of the 
automated treatment to be compared. These challenges are not unique to doctoral 
research and are often encountered in clinical research, particularly with virtual reality. I 
was fortunate to be integrated into a team with expertise in the area, including computer 
scientists specialising in virtual reality. If this project was completed in an external site 
with less support, it is likely that there would have been many additional challenges that 
would have affected the overall running of the study. On reflection, this is similar to the 
boundaries of clinical research, the influence of grants on academic curiosity, and the 
need for support in the completion of larger projects.  
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One of the challenges of developing a cohesive thesis was to avoid tackling 
large concepts or multiple problems and to design a study that would be targeted and 
informative. As highlighted in the review, virtual reality is not a new idea, but it is 
continuously evolving and can be used to create environments that are not possible in 
the real world. The untapped potential of virtual reality also means there are many 
research avenues to follow but environments can quickly become outdated. This is one 
of the main reasons for looking at mechanisms and treatment components as it has the 
potential to inform future therapeutic content.  
Similar to the systematic review, the empirical project was narrowed down 
following discussions with my supervisors and consulting the evidence base. My 
primary research interest was how virtual reality as a treatment modality could be 
enhanced. It was suspected that most studies used hierarchical exposure models and 
were not updating these approaches according to current research. This was supported 
by the systematic review. Therefore, the purpose of the empirical project was to use 
newer approaches to exposure to inform augmentations that would be compared to a 
control condition. This would expand the research on the mechanisms of exposure and 
explore methods of enhancing virtual reality. The automated treatment used for this 
study differed from most of the research as it used a series of behavioural experiments 
on each level and incorporated many of the recommendations used by Craske and 
colleagues (2014) that formed the theoretical basis of the augmentation. It also used a 
virtual therapist, which provided a controlled environment to test the manipulation. This 
treatment had also been tested in a randomised controlled trial prior to the empirical 
study so there was existing data that supported it as an effective treatment for fear of 
heights.  
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  Challenges of the empirical project 
  The recruitment targets set out for the empirical study were met within an 
appropriate timeframe and testing was completed to schedule. The manipulation was 
also effective, and the study ran largely as planned. However, there were a number of 
challenges that were overcome that will be discussed.  
One of the main challenges with the empirical project was the size of the sample and 
the time that was required to screen and test participants. An approximate time to 
complete the study was anticipated as I had previous experience with virtual reality 
research and had worked on a non-clinical study prior to training. I also piloted the 
study before opening recruitment to establish a clear testing time frame. This meant I 
had existing knowledge of recruitment schedules, how long it would take to test, how 
many I could see in a day, and how to use the technology in a trial scenario. I was also 
familiar with the Department of Psychiatry at the University of Oxford, where the study 
was run, and had existing relationships with the clinical research team. This was 
invaluable as participants often had to be tested in the evenings and at weekends, which 
meant a member of the department was required to be in the building to conform with 
lone working policies. Integrating myself into the research team for the duration of the 
project also allowed me to access computer support and to overcome any issues with the 
technology. 
The main challenges when working with virtual reality are unavoidable 
incompatibilities between scenarios that are developed externally, and hardware. The 
technology has noticeably advanced and it is relatively easy to use but glitches do occur, 
and the solutions aren’t always obvious. The most common glitches during the study 
were losing tracking (participant is no longer mirrored by the avatar), the scenario 
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freezing, and losing connection with the handsets. These were most problematic at the 
start of the study as it took time to learn how to fix common errors before starting the 
scenario. I also swapped the headset after the first ten participants from a wireless to 
wired set up. This removed the tracking errors and prevented participants from losing 
presence mid scenario. It was important to find a solution to this error as losing 
presence also increased the likelihood that participants would use cognitive safety 
behaviours such as, “it isn’t real” or “I’m in VR, I’m safe”, to assist them with the tasks. 
Some reliance on safety behaviours during the intervention was expected but where 
possible, participants should be encouraged to engage with their environment as they 
would in the real world to maximise new learning. The within group reduction in 
conviction across the whole sample actually suggests losing presence is less important 
than predicted as participants were removed from virtual reality twice to complete the 
manipulation. This created a larger break in presence than losing tracking, but the latter 
was unexpected when it occurred, which may have been more problematic. 
 As expected, there were challenges with recruitment due to the time restraints of the 
doctorate. This was largely related to poor planning at the start as I received a large 
number of responses in the first few weeks that I didn’t have the capacity to follow up 
and test during my allocated research days. This invariably led to a loss of some 
participants who did not receive a timely response. It also meant that the second wave of 
recruitment received less response as it targeted the same population and was run a few 
weeks before Christmas. On reflection, I should have created a written recruitment plan 
that would have accounted for time required to follow up participants, testing time, data 
management and unexpected issues with the equipment.  
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Impact and dissemination 
Clinical impact 
It is hoped that the systematic review and the empirical study will be informative 
for researchers and clinicians in the development and use of virtual reality as a treatment 
for mental health disorders. The finding that most virtual reality treatments for phobias 
use hierarchical exposure models highlights the issue that therapeutic content is not 
being updated. This is informative for researchers seeking to develop new environments 
and to consider how virtual reality should be used. It also suggests re-considering using 
scenarios that are unachievable in the real world and adopting models of exposure that 
are in line with current research. As the technology is now more available and easier to 
use, these treatments are already being developed for clinical use. Therefore, the review 
findings have the potential to help shape the next generation of virtual reality treatments 
for phobias. This will be particularly relevant as virtual reality moves towards being a 
stand-alone treatment such as the automated treatment trialled by Freeman et al (2018) 
that was also used in the empirical study. The review highlighted that many therapeutic 
components reported in trials of virtual reality are delivered externally to the virtual 
environment. Therefore, if automation is a real possibility, as Freeman et al. (2018) 
suggest, virtual environments have to be re-designed to incorporate these components. 
To some extent this may require re-designing old scenarios but there is potential for 
modification in the interim such as, progression based on belief change rather than self-
reported fear or distress.  
Findings from the systematic review suggest large post-test effect sizes are 
deceptive as follow up data is not always reported, and most scenarios rely on 
habituation which is vulnerable to fear renewal. It also raises questions about the 
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methods of measuring change, when and how this is achieved, and which mechanisms 
are being targeted in the intervention. In the empirical paper, two commonly used fear 
of heights measures (AQ and ATHQ) were not correlated with beliefs about heights yet 
pre and post belief conviction scores were strongly correlated. Researchers should 
therefore consider the possibility that the measures they use do not capture cognitive 
change and that a combination of measures or behavioural avoidance tests may be 
required to overcome these issues.      
When considering the clinical impact of the review and the empirical study, it is 
important to recognise that although virtual reality is expected to be integrated into 
clinical teams in the coming years, it is still in the developmental phase. In the long 
term, the potential is that psychological interventions can be delivered to many more 
people without the need for specialist skills. In the short term, these treatments need to 
be prepared and tested for clinical use and researchers need to understand more about 
the treatment mechanisms specific to virtual reality. The finding from the empirical 
paper that physiological arousal is not required for cognitive change is informative for 
both areas of development. Clinically, it means that outcomes are not dependent on fear 
responses within virtual reality and that these treatments are somewhat robust to breaks 
in presence. In relation to future research, it suggests virtual scenarios should prioritise 
components that target cognitive change instead of increasing overall fear arousal. In 
the review, it was highlighted that researchers are often too concerned with how realistic 
the virtual environment is to the user in order to achieve maximum immersion and 
arousal. Interestingly, this approach is flawed as a method of raising fear responses 
regardless of whether it is effective at creating cognitive change as existing research on 
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presence suggests immersion in virtual reality is not dependent the quality of the 
graphics (Slater, 2009). 
Dissemination 
The systematic review and the empirical study will be edited and submitted for 
publication following completion of the doctorate. The systematic review will be 
submitted to ‘Cyberpsychology, Behavior and Social Networking’. This is a peer-
reviewed journal with an impact factor of 2.689 that publishes research to further 
understanding of the ‘psychological impact’ of communication technologies. It has 
published articles on the application and understanding of virtual reality technology for 
over 20 years and would be viewed by researchers developing, testing or augmenting 
new environments for mental health disorders.        
The empirical study will be submitted to ‘Behaviour Research and Therapy’.  
This is a peer-reviewed, multi-disciplinary journal with an impact factor of 4.134. The 
aims of the journal are to increase understanding of the treatment and prevention of 
emotional and behavioural disorders. The journal has a strong focus on cognitive 
behavioural techniques, psychophysiological methodologies, experimental designs and 
studies that examine treatment mechanisms, moderators and mediators, and novel 
treatments. The empirical study investigated a potential mechanism of change by 
manipulating physiological arousal in a controlled, experimental setting so it was 
considered appropriate for the remit of this journal.  
Conclusion 
The purpose of this study was to examine how virtual reality is being applied in 
the treatment of specific phobias and to investigate treatment mechanisms and to 
improve intervention outcomes. This was an ambitious project that developed my 
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general research skills that included: designing and co-ordinating a study, recruitment, 
data management, data analysis, and using virtual reality within the context of research. 
There were a number of challenges that were overcome to meet recruitment targets, 
notably, completing over 100hrs of testing whilst managing the other demands of the 
clinical doctorate. One of the main process reflections related to the systematic review, 
which was completed prior to submission of the study protocol. Conducting a 
systematic review gave me an in depth understanding of the subject area, which would 
have been informative at the design stage. Whilst this was not possible due to time 
constraints of the doctorate, it highlighted the importance of thoroughly consulting the 
literature in the planning stage of research and the added value of systematically 
evaluating the evidence. It is hoped that this research will be of value to academics and 
clinicians in the development of virtual reality treatments and will inform a larger body 
of work post qualification.  
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Appendix C. Participant debrief information sheet 
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Appendix C (continued). 
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Appendix D. Recruitment tools 
Appendix D1. Poster 
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Appendix D2. Radio advert  
 
Do you have a fear of heights? Would you be interested in taking part in psychological 
research in virtual reality? At the University of Oxford, we're looking for volunteers to 
take part in a study investigating the effects of physical exercise on a virtual reality 
treatment for fear of heights. If you're interested then please text the word STUDY to 
[insert number] for more information. That's STUDY to [insert number
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Appendix E.  Measures 
Appendix E1. Screening measure, Acrophobia Questionnaire (AQ) 
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Appendix E1 (continued). 
 
 
157 
 
 
Appendix E1 (continued). 
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Appendix E1 (continued). 
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Appendix E1 (continued). 
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Appendix E2. Belief of heights conviction and self-efficacy
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Appendix E3. Brief Safety Behaviour Inventory (SBI)  
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Appendix E3 (continued). 
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Appendix E4. Risk orientation scale (ROS) 
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Appendix E5. Attitudes towards heights questionnaire (ATHQ) 
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Appendix E6. The Anxiety Attitude and Belief Scale (AABS-R 33)  
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Appendix E6 (continued). 
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Appendix E6 (continued). 
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Appendix E7. Anxiety sensitivity index – 3 (ASI-3) 
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Appendix E8. Beck depression inventory (BDI) 
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Appendix E9. Beck anxiety inventory (BAI) 
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Appendix E10. Subjective units of distress and self-efficacy record sheet  
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Appendix F: Images of the virtual scenario 
Appendix F1: Virtual therapist 
 
 
Appendix F2: Atrium 
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Appendix F3: Throwing balls over the edge 
 
 
 
Appendix F3: Throwing balls over the edge 
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Appendix G. Participant information sheet 
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Appendix G (continued). 
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Appendix G (continued) 
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Appendix G (continued) 
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Appendix H. Consent form
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Appendix I. Baseline mean scores on predictor variables   
  
Exercise: 
mean (SD) 
 
Control: 
mean (SD) 
 
Overall mean (SD) 
 
BAI 
 
9.55 (9.02) 
 
8.40 (7.21) 
 
8.88 (8.12) 
SBI (physical vigilance) 4.13 (2.66) 3.80 (1.67) 3.97 (2.21) 
SBI (cleanliness) 2.73 (2.72) 2.63 (2.21) 2.68 (2.45) 
SBI (checking) 2.70 (2.12) 2.03 (1.65) 2.37 (1.91) 
ASI-3 (physical sensitivity) 7.30 (4.86) 7.27 (4.50) 7.28 (4.64) 
ASI-3 (cognitive sensitivity) 5.93 (5.16) 4.63 (3.70) 5.28 (4.50) 
ASI-3 (social sensitivity) 12.10 (5.12) 10.87 (4.27) 11.48 (4.71) 
ASI-3 total score 25.33 (11.45) 22.77 (9.57) 24.05 (10.54) 
AABS2-R-33 117.53 (28.35) 116.4 (30.32) 116.98 (29.10) 
BDI  10.62 (10.42) 9.38 (6.76) 10.00 (8.74) 
ATHQ (cognitive subscale) 22.60 (5.16) 21.43 (6.35) 22.02 (5.77) 
ATHQ (danger subscale) 24.07 (4.19) 23.60 (4.66) 23.83 (4.40) 
Abbreviations: BAI, Beck Anxiety Inventory; SBI, Safety Behaviours Inventory; ASI-3, Anxiety Sensitivity Index 3; AABS2-33, The Anxiety 
Attitude and Belief Scale (33 item); ROS, Risk Orientation Scale 
181 
 
Appendix I (continued). 
ROS (financial risk) 159.33 (80.68) 190.67 (88.12) 175.00 (85.24) 
ROS (social risk) 285.00 (90.81) 326.33 (88.42) 305.67 (91.27) 
ROS (physical risk) 146.67 (88.72) 162.67 (103.82) 154.67 (96.08) 
Self-efficacy heights 36.22 (26.01) 35.17 (26.11) 35.69 (25.89) 
Self-efficacy heights in VR 58.5 (26.04) 60.50 (21.39) 59.50 (23.65) 
Conviction (pre) 69.42 (22.78) 70.33 (21.77) 69.88 (22.11) 
Abbreviations: BAI, Beck Anxiety Inventory; SBI, Safety Behaviours Inventory; ASI-3, Anxiety Sensitivity Index 3; AABS2-33, The Anxiety Attitude 
and Belief Scale (33 item); ROS, Risk Orientation Scale 
 
 
